IE49321B1 - Derivatives of mercaptoacyl prolines and pipecolic acids - Google Patents
Derivatives of mercaptoacyl prolines and pipecolic acidsInfo
- Publication number
- IE49321B1 IE49321B1 IE2468/79A IE246879A IE49321B1 IE 49321 B1 IE49321 B1 IE 49321B1 IE 2468/79 A IE2468/79 A IE 2468/79A IE 246879 A IE246879 A IE 246879A IE 49321 B1 IE49321 B1 IE 49321B1
- Authority
- IE
- Ireland
- Prior art keywords
- hydrogen
- lower alkyl
- compound
- methyl
- oxopropyl
- Prior art date
Links
- 239000002253 acid Substances 0.000 title claims description 54
- 150000003148 prolines Chemical class 0.000 title claims description 4
- 235000013930 proline Nutrition 0.000 title description 11
- 150000007513 acids Chemical class 0.000 title description 3
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 92
- 239000001257 hydrogen Substances 0.000 claims abstract description 91
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 91
- -1 Mercapto acyl compounds Chemical class 0.000 claims abstract description 43
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 35
- 150000003839 salts Chemical class 0.000 claims abstract description 31
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 19
- 125000006239 protecting group Chemical group 0.000 claims abstract description 14
- 125000004414 alkyl thio group Chemical group 0.000 claims abstract description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000001301 oxygen Substances 0.000 claims abstract description 9
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 83
- 150000001875 compounds Chemical class 0.000 claims description 64
- 150000002431 hydrogen Chemical class 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 25
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 23
- 229910052717 sulfur Inorganic materials 0.000 claims description 22
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 14
- 125000005843 halogen group Chemical group 0.000 claims description 14
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 12
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 125000001246 bromo group Chemical group Br* 0.000 claims description 8
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000001153 fluoro group Chemical group F* 0.000 claims description 8
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 7
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 7
- 239000011593 sulfur Substances 0.000 claims description 7
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 150000003573 thiols Chemical class 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 5
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical class [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 239000002934 diuretic Substances 0.000 claims description 5
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Chemical class OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 claims description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 4
- 230000001882 diuretic effect Effects 0.000 claims description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 12
- 125000001589 carboacyl group Chemical group 0.000 claims 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 2
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 claims 2
- 150000001298 alcohols Chemical class 0.000 claims 1
- 238000007796 conventional method Methods 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 239000005864 Sulphur Substances 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 125000000962 organic group Chemical group 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 177
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 138
- 229960002429 proline Drugs 0.000 description 103
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 84
- 239000000047 product Substances 0.000 description 78
- 239000000243 solution Substances 0.000 description 65
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 64
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- 239000002904 solvent Substances 0.000 description 42
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 39
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
- 239000007787 solid Substances 0.000 description 34
- 229910021529 ammonia Inorganic materials 0.000 description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 32
- 239000010410 layer Substances 0.000 description 28
- 238000001816 cooling Methods 0.000 description 26
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 24
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 23
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 22
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000012044 organic layer Substances 0.000 description 20
- 239000008346 aqueous phase Substances 0.000 description 18
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- 239000003921 oil Substances 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 238000003756 stirring Methods 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- 229910052786 argon Inorganic materials 0.000 description 12
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 12
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 11
- 238000001704 evaporation Methods 0.000 description 11
- 239000000543 intermediate Substances 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 229910000029 sodium carbonate Inorganic materials 0.000 description 11
- 230000008020 evaporation Effects 0.000 description 10
- RPLLCMZOIFOBIF-NSHDSACASA-N (2s)-4-oxo-1-phenylmethoxycarbonylpyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CC(=O)CN1C(=O)OCC1=CC=CC=C1 RPLLCMZOIFOBIF-NSHDSACASA-N 0.000 description 9
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 9
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 239000006188 syrup Substances 0.000 description 8
- 235000020357 syrup Nutrition 0.000 description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 238000010899 nucleation Methods 0.000 description 7
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 7
- JTNCEQNHURODLX-UHFFFAOYSA-N 2-phenylethanimidamide Chemical compound NC(=N)CC1=CC=CC=C1 JTNCEQNHURODLX-UHFFFAOYSA-N 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 6
- 239000008120 corn starch Substances 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 150000003946 cyclohexylamines Chemical class 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 239000011630 iodine Substances 0.000 description 6
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 6
- 150000004702 methyl esters Chemical class 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 159000000000 sodium salts Chemical class 0.000 description 6
- KUSYIGBGHPOWEL-UHFFFAOYSA-N 2-methyl nonaoic acid Chemical compound CCCCCCCC(C)C(O)=O KUSYIGBGHPOWEL-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 101800000734 Angiotensin-1 Proteins 0.000 description 4
- 102400000344 Angiotensin-1 Human genes 0.000 description 4
- 108010064733 Angiotensins Proteins 0.000 description 4
- 102000015427 Angiotensins Human genes 0.000 description 4
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 238000005917 acylation reaction Methods 0.000 description 4
- 125000005907 alkyl ester group Chemical group 0.000 description 4
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 4
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 4
- 229960002003 hydrochlorothiazide Drugs 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- TZBHHPYGZROULI-UHFFFAOYSA-N s-(3-chloro-2-methylsulfanyl-3-oxopropyl) ethanethioate Chemical compound CSC(C(Cl)=O)CSC(C)=O TZBHHPYGZROULI-UHFFFAOYSA-N 0.000 description 4
- 238000005245 sintering Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 4
- HGJZUVHTFSPDPZ-MQWKRIRWSA-N (2s)-4,4-dimethoxy-1-(2-methyl-3-sulfanylpropanoyl)pyrrolidine-2-carboxylic acid Chemical compound COC1(OC)C[C@@H](C(O)=O)N(C(=O)C(C)CS)C1 HGJZUVHTFSPDPZ-MQWKRIRWSA-N 0.000 description 3
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 3
- MHFRNHRKLAYQIE-UHFFFAOYSA-N 6,10-dioxo-2-azaspiro[4.5]decane-3-carboxylic acid Chemical compound O=C1C2(CC(NC2)C(=O)O)C(CCC1)=O MHFRNHRKLAYQIE-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 229930182821 L-proline Natural products 0.000 description 3
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 3
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 239000000908 ammonium hydroxide Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 229960002591 hydroxyproline Drugs 0.000 description 3
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 description 3
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 3
- 239000011736 potassium bicarbonate Substances 0.000 description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- XYZNAPXKDLKKRG-ZETCQYMHSA-N (2s)-4,4-diethoxypyrrolidine-2-carboxylic acid Chemical compound CCOC1(OCC)CN[C@H](C(O)=O)C1 XYZNAPXKDLKKRG-ZETCQYMHSA-N 0.000 description 2
- SFSROLZHCPCODJ-WCCKRBBISA-N (2s)-4-oxopyrrolidine-2-carboxylic acid;hydrobromide Chemical compound Br.OC(=O)[C@@H]1CC(=O)CN1 SFSROLZHCPCODJ-WCCKRBBISA-N 0.000 description 2
- DYKOKCJMIUBXTR-ZETCQYMHSA-N (3s)-6,9-dioxo-2-(3-sulfanylpropanoyl)-2-azaspiro[4.4]nonane-3-carboxylic acid Chemical compound C1N(C(=O)CCS)[C@H](C(=O)O)CC21C(=O)CCC2=O DYKOKCJMIUBXTR-ZETCQYMHSA-N 0.000 description 2
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 2
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- GVCARDRZNAPXPT-UHFFFAOYSA-N 2-methylsulfanylprop-2-enoic acid Chemical compound CSC(=C)C(O)=O GVCARDRZNAPXPT-UHFFFAOYSA-N 0.000 description 2
- PSGUKONEIBCWQN-UHFFFAOYSA-N 3,3,3-trifluoro-2-[(4-methoxyphenyl)methylsulfanylmethyl]propanoyl chloride Chemical compound COC1=CC=C(CSCC(C(Cl)=O)C(F)(F)F)C=C1 PSGUKONEIBCWQN-UHFFFAOYSA-N 0.000 description 2
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 2
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 2
- AZSXBSYVGBDHTA-UHFFFAOYSA-N 3-acetylsulfanyl-2-methylsulfanylpropanoic acid Chemical compound CSC(C(O)=O)CSC(C)=O AZSXBSYVGBDHTA-UHFFFAOYSA-N 0.000 description 2
- PSPOEQSCJVBCDR-UHFFFAOYSA-N 3-oxobutanethioyl chloride Chemical compound CC(=O)CC(Cl)=S PSPOEQSCJVBCDR-UHFFFAOYSA-N 0.000 description 2
- UNUDUTMFKRKUIJ-UHFFFAOYSA-N 4-oxopentanethioyl chloride Chemical compound CC(=O)CCC(Cl)=S UNUDUTMFKRKUIJ-UHFFFAOYSA-N 0.000 description 2
- UYLDJKGHDNEMOP-UHFFFAOYSA-N 5-oxohexanethioyl chloride Chemical compound CC(=O)CCCC(Cl)=S UYLDJKGHDNEMOP-UHFFFAOYSA-N 0.000 description 2
- MYKRRNSELLQFIW-UHFFFAOYSA-N 6,9-dioxo-2-azaspiro[4.4]nonane-3-carboxylic acid Chemical compound O=C1CCC(C11CNC(C1)C(=O)O)=O MYKRRNSELLQFIW-UHFFFAOYSA-N 0.000 description 2
- 102000005862 Angiotensin II Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- 102000004881 Angiotensinogen Human genes 0.000 description 2
- 108090001067 Angiotensinogen Proteins 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229930194542 Keto Natural products 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000005915 ammonolysis reaction Methods 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 125000001891 dimethoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- DUYAAUVXQSMXQP-UHFFFAOYSA-N ethanethioic S-acid Chemical compound CC(S)=O DUYAAUVXQSMXQP-UHFFFAOYSA-N 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 150000003147 proline derivatives Chemical class 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical group CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- SITTWQPUINJZTD-UHFFFAOYSA-N s-(3-chloro-2,2-dimethyl-3-oxopropyl) ethanethioate Chemical compound CC(=O)SCC(C)(C)C(Cl)=O SITTWQPUINJZTD-UHFFFAOYSA-N 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical group OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- RRJPAPPBVFHVJQ-QMMMGPOBSA-N (2s)-1-(2-acetylsulfanylacetyl)-4,4-dimethoxypyrrolidine-2-carboxylic acid Chemical compound COC1(OC)C[C@@H](C(O)=O)N(C(=O)CSC(C)=O)C1 RRJPAPPBVFHVJQ-QMMMGPOBSA-N 0.000 description 1
- CDMYKWMRONJQDV-LBPRGKRZSA-N (2s)-4,4-dimethoxy-1-phenylmethoxycarbonylpyrrolidine-2-carboxylic acid Chemical compound C1C(OC)(OC)C[C@@H](C(O)=O)N1C(=O)OCC1=CC=CC=C1 CDMYKWMRONJQDV-LBPRGKRZSA-N 0.000 description 1
- WWVCWLBEARZMAH-DTIOYNMSSA-N (2s)-4-hydroxy-1-phenylmethoxycarbonylpyrrolidine-2-carboxylic acid Chemical compound C1C(O)C[C@@H](C(O)=O)N1C(=O)OCC1=CC=CC=C1 WWVCWLBEARZMAH-DTIOYNMSSA-N 0.000 description 1
- DXFZQTUGGMMSMH-JAMMHHFISA-N (3s)-2-(2-methylsulfanyl-3-sulfanylpropanoyl)-6,9-dioxo-2-azaspiro[4.4]nonane-3-carboxylic acid Chemical compound C1[C@@H](C(O)=O)N(C(=O)C(CS)SC)CC21C(=O)CCC2=O DXFZQTUGGMMSMH-JAMMHHFISA-N 0.000 description 1
- BAPAPYNGKSPYCX-GKAPJAKFSA-N (3s)-2-[2-(acetylsulfanylmethyl)-3,3,3-trifluoropropanoyl]-6,9-dioxo-2-azaspiro[4.4]nonane-3-carboxylic acid Chemical compound C1[C@@H](C(O)=O)N(C(=O)C(CSC(=O)C)C(F)(F)F)CC21C(=O)CCC2=O BAPAPYNGKSPYCX-GKAPJAKFSA-N 0.000 description 1
- PTCYIWMGYCDFJR-MLWJPKLSSA-N (3s)-6,9-dioxo-2-[3,3,3-trifluoro-2-(sulfanylmethyl)propanoyl]-2-azaspiro[4.4]nonane-3-carboxylic acid Chemical compound C1N(C(=O)C(CS)C(F)(F)F)[C@H](C(=O)O)CC21C(=O)CCC2=O PTCYIWMGYCDFJR-MLWJPKLSSA-N 0.000 description 1
- PUJPJMMOBSFICS-JAMMHHFISA-N (8s)-7-(2-methylsulfanyl-3-sulfanylpropanoyl)-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid Chemical compound C1[C@@H](C(O)=O)N(C(=O)C(CS)SC)CC21SCCS2 PUJPJMMOBSFICS-JAMMHHFISA-N 0.000 description 1
- OTSXNWBMDPQPHE-LBPRGKRZSA-N (8s)-7-phenylmethoxycarbonyl-1,4-dioxa-7-azaspiro[4.4]nonane-8-carboxylic acid Chemical compound C([C@H](N(C1)C(=O)OCC=2C=CC=CC=2)C(=O)O)C21OCCO2 OTSXNWBMDPQPHE-LBPRGKRZSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- VLSRKCIBHNJFHA-UHFFFAOYSA-N 2-(trifluoromethyl)prop-2-enoic acid Chemical compound OC(=O)C(=C)C(F)(F)F VLSRKCIBHNJFHA-UHFFFAOYSA-N 0.000 description 1
- SRXRBNCPSVMKIE-UHFFFAOYSA-N 2-azaspiro[4.4]nonane-3-carboxylic acid Chemical compound C1NC(C(=O)O)CC11CCCC1 SRXRBNCPSVMKIE-UHFFFAOYSA-N 0.000 description 1
- JIVPVXMEBJLZRO-CQSZACIVSA-N 2-chloro-5-[(1r)-1-hydroxy-3-oxo-2h-isoindol-1-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC([C@@]2(O)C3=CC=CC=C3C(=O)N2)=C1 JIVPVXMEBJLZRO-CQSZACIVSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- SBJPKUSFMZKDRZ-UHFFFAOYSA-N 2-methylsulfanylpropanoic acid Chemical compound CSC(C)C(O)=O SBJPKUSFMZKDRZ-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- GZGBVRKSXMCBPV-UHFFFAOYSA-N 3,3,3-trifluoro-2-[(4-methoxyphenyl)methylsulfanylmethyl]propanoic acid Chemical compound COC1=CC=C(CSCC(C(O)=O)C(F)(F)F)C=C1 GZGBVRKSXMCBPV-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- HFXAFXVXPMUQCQ-BYPYZUCNSA-N 4-oxo-L-proline Chemical compound OC(=O)[C@@H]1CC(=O)CN1 HFXAFXVXPMUQCQ-BYPYZUCNSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- YCYQWACWSNYMMR-UHFFFAOYSA-N 8,9-dioxo-2-azaspiro[4.4]nonane-3-carboxylic acid Chemical compound O=C1C(C2(CC1)CNC(C2)C(=O)O)=O YCYQWACWSNYMMR-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 244000186140 Asperula odorata Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 235000008526 Galium odoratum Nutrition 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- VJRJAKYWBVMEJU-VWMHFEHESA-N N-cyclohexylcyclohexanamine (2S)-pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1.C1CCC(CC1)NC1CCCCC1 VJRJAKYWBVMEJU-VWMHFEHESA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- ZCLSQRQRWNDNLV-UHFFFAOYSA-N acetic acid;dichloromethane;methanol Chemical compound OC.ClCCl.CC(O)=O ZCLSQRQRWNDNLV-UHFFFAOYSA-N 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 150000003974 aralkylamines Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- NDTSRXAMMQDVSW-UHFFFAOYSA-N benzthiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1N=C2CSCC1=CC=CC=C1 NDTSRXAMMQDVSW-UHFFFAOYSA-N 0.000 description 1
- 229960001541 benzthiazide Drugs 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- NSXKVMCVAPWBAV-UHFFFAOYSA-N butanethioyl chloride Chemical compound CCCC(Cl)=S NSXKVMCVAPWBAV-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 1
- 229940005991 chloric acid Drugs 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 229960001523 chlortalidone Drugs 0.000 description 1
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
- 150000001844 chromium Chemical class 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 150000004662 dithiols Chemical class 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 description 1
- 229960003199 etacrynic acid Drugs 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- RGUQWGXAYZNLMI-UHFFFAOYSA-N flumethiazide Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O RGUQWGXAYZNLMI-UHFFFAOYSA-N 0.000 description 1
- 229960003028 flumethiazide Drugs 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- AWIJRPNMLHPLNC-UHFFFAOYSA-N methanethioic s-acid Chemical compound SC=O AWIJRPNMLHPLNC-UHFFFAOYSA-N 0.000 description 1
- BLWYXBNNBYXPPL-YFKPBYRVSA-N methyl (2s)-pyrrolidine-2-carboxylate Chemical compound COC(=O)[C@@H]1CCCN1 BLWYXBNNBYXPPL-YFKPBYRVSA-N 0.000 description 1
- AWJZTPWDQYFQPQ-UHFFFAOYSA-N methyl 2-chloroprop-2-enoate Chemical compound COC(=O)C(Cl)=C AWJZTPWDQYFQPQ-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229960005483 polythiazide Drugs 0.000 description 1
- 229920000046 polythiazide Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- ZJLMKPKYJBQJNH-UHFFFAOYSA-N propane-1,3-dithiol Chemical group SCCCS ZJLMKPKYJBQJNH-UHFFFAOYSA-N 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960005359 propylparaben sodium Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- JREMHUJYFXNYSW-UHFFFAOYSA-N s-(2-carbonochloridoyl-3,3,3-trifluoropropyl) ethanethioate Chemical compound CC(=O)SCC(C(Cl)=O)C(F)(F)F JREMHUJYFXNYSW-UHFFFAOYSA-N 0.000 description 1
- XEYWOETXQNDSED-UHFFFAOYSA-N s-(3-chloro-3-oxopropyl) ethanethioate Chemical compound CC(=O)SCCC(Cl)=O XEYWOETXQNDSED-UHFFFAOYSA-N 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000009491 slugging Methods 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- IXMINYBUNCWGER-UHFFFAOYSA-M sodium;4-propoxycarbonylphenolate Chemical compound [Na+].CCCOC(=O)C1=CC=C([O-])C=C1 IXMINYBUNCWGER-UHFFFAOYSA-M 0.000 description 1
- 150000003413 spiro compounds Chemical class 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- AGHANLSBXUWXTB-UHFFFAOYSA-N tienilic acid Chemical compound ClC1=C(Cl)C(OCC(=O)O)=CC=C1C(=O)C1=CC=CS1 AGHANLSBXUWXTB-UHFFFAOYSA-N 0.000 description 1
- 229960000356 tienilic acid Drugs 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- 229960004813 trichlormethiazide Drugs 0.000 description 1
- LMJSLTNSBFUCMU-UHFFFAOYSA-N trichlormethiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC(C(Cl)Cl)NS2(=O)=O LMJSLTNSBFUCMU-UHFFFAOYSA-N 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical group CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/10—Spiro-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Mercapto acyl compounds, having hypotensive activity, have the formula:- or are salts thereof, wherein R is hydrogen or lower alkyl, R1 and R2 are various defined organic groups or R1 and R2 together complete a ring, X1 and X2 are oxygen or sulphur, one of p and q is 1 and the other is 1 or 2, R3 and R4 are hydrogen lower alkyl, lower alkyl thio, -(CH2)n SH or halo lower alkyl, (n being from 1 to 3), R6 is hydrogen or (when R3 is lower alkyl) lower alkyl, m is 0, 1 or 2 and R5 is hydrogen or a protecting group.
Description
This invention relates to new derivatives of mercaptoacyl prolines and pipecolic acids of formula I and salts thereof (I) x, x2 Ac/2 R--S-(CH) -C -C· 5 m . 7¾ C-COOR R and R are independently selected from hydrogen and lower alkyl provided that Rg is lover alkyl only if R^ is also lower alkyl.
R3 and R^ are independently selected from hydrogen, lower alkyl, lower alkylthio, -{CH^^-SH, and halo substituted lower alkyl. χ , X2 and X^ are independently selected fromoxygen and sulfur.
R^ . and. Rj are independently selected from lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, halo substituted lower alkyl, hydroxy substituted lower alkyl, -(CH2)r<® ' -
When R^ and R2 are joined together in a polymethylene chain of 2 or 3 carbons, these cyclic ketal and thioketals can be represented as follows; R. Ί R, 0 ‘9 *10^ *9 R. ‘10 R.
S S wherein t is 2 or 3 and Rg and R1(J are both hydrogen, both lower alkyl, or one is hydrogen and the other is lower alkyl, halo substituted lower alkyl, hydroxy substituted lower alkyl, —— R. '7 Preferably, only one carbon of the polymethylene chain will be substituted.
R7 is hydrogen, lower alkyl of 1 to 4 carbons, especially methyl, lower alkoxy of 1 to 4 carbons, especially methoxy, lower alkylthio of 1 to 4 carbons, especially methylthio, chloro, bromo, fluoro, trifluoromethyl, or hydroxy.
R5 is hydrogen, a hydrolyzab1y removable protecting group, a chemically removable protecting group, or when R3 and R^ are other than -(CH2)n-SH a sulfide of the formula R1 R2 I X, X•x \ (H,C) 2, P Wq N -C-COOR I* H one, or two.
-S-(CH) -C- C m , R6 m is zero, n is one, two. or three. p and q are each one or two provided that both are not tw*.
The asterisk in the above formula indicates 15 a center of asymmetry in the ring. In the case of proline, i.e., p and q are both one, this center is in the L-configuration. In the case of pipecolic acid, i.e., one of p and q is two, this center is in the D, L or L-configuration.
Asymmetric centers can also be present in the mercaptoacyl sidechain depending upon the definition of Rj, R4 and Rg. Another assynroetric center may also be present in the ring when X^-R^ and different, products can accordingly exist in stereoisomeric forms or as racemic mixtures thereof. All of these are within the scope of the invention. lhe synthesis described below can utilize the racemate or one of the enantiomers as starting materials. When the racenic starting material is used in the synthesis procedure, the stereoisomers obtained in final product can be separated by conventional chromatographic or fractional crystallization methods 48321 - 5 Preferably, if there is an asymmetric center in the mercaptoacyl sidechain, it is in the D-configuration.
This invention in its broadest aspect relates to the mercaptoacyl derivatives of proline and pipecolic acid having formula I above and to salts thereof, to compositions containing such compounds and to the method for using such compounds as anti-hypertensive agents. This invention is also directed to certain novel intermediates useful in the preparation of compounds of formula I.
The term lower alkyl as used in defining the symbols R, R^, Rj, R^' K4' an^ Rg are straight or branched chain hydrocarbon radicals having up to seven carbons, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, isopentyl, etc. The preferred lower alkyl groups are up to four carbons with methyl and ethyl being most preferred. Similarly, the terms lower alkoxy and lower alkylthio refer to such lower alkyl groups attached to an oxygen or sulfur.
The term cycloalkyl refers to saturated rings of 3 to 7 carbon atoms with cyclohexyi being most preferred.
The term halo substituted lower alkyl refers to such lower alkyl groups described above in which one or more hydrogens have been replaced by chloro, bromo or fluoro groups such as trifluoromethyl, pentafluoroethyl, 2,2,2-trichloroethyl, chloromethyl, 8-3 21 bromomethyl, etc.
The term hydroxy substituted lower alkyl refers to such lower alkyl groups described above in which one hydrogen has been replaced by a hydroxy group such as hydroxymethyl, 2-hydroxyethyl, etc.
The term lower alkenyl as used in defining the symbols R^ and R2 are mono-unsaturated straight'or branched chain hydrocarbon groups of from 2 to 7 carbons such as ethenyl, propenyl, isopropenyl, butenyl, and the like. The lower alkynyl groups are straight or branched chain hydrocarbon groups of from 2 to 7 carbons having one triple bond, e.g., propargyl. The preferred lower alkenyl groups are from 2 to 5 carbons and the preferred lower alkynyl groups are from 2 to 4 carbon atoms.
The term hydrolyzably removable protecting group employed in defining R^ refers to a group that can be removed by conventional hydrolysis or 0 h ammonolysis. Acyl groups of the formula Rg~Care suitable for this purpose wherein Ηθ can be lower alkyl of 1 to 7 carbons, lower alkyl substituted with one or more chloro, bromo or fluoro groups, ~(CH2)r~cycloalkyl, an aryl'group such as -(CH2) a hetero group such as Jj, or ~(^H2^r |O wherein r is zero, one, two or three, and R? and are as defined above. 4-9321 - 7 Preferred groups ar4 the lower alkanoyl groups having up to four carbons, especially acetyl, and benzoyl.
The term chemically removable protecting group employed in defining Rg refers to groups such as p-methoxybenzyl, p-methoxybenzyloxycarbonyl, trityl, t-butoxycarbonyl, etc. These groups can be removed after the completion of the acylation reaction hy various means depending upon the definition of X^-R^ and X2"R2 such as treatment with trifluoroacetic acid and anisole, sodium and liguid ammonia, or mercuric-trifluoroacetate.
Preferred compounds of formula I are the Lproline containing derivative, i.e., p and g are both one, and R is hydrogen.
With respect to the mercaptoacyl sidechain, preferred as final products are those compounds wherein Rg is hydrogen; m is zero or one; R^ is hydrogen; and.Rg and Rg are both lower alkyl of 1 to 4 carbons, especially both methyl, or Rg is hydrogen and Rg is hydrogen, lower alkyl of 1 to 4 carbons, especially methyl, trifluoromethyl, methylthio, or mercaptomethyl. Also preferred as both intermediates and final products are the above sidechains wherein Rg is lower alkanoyl or 1 to 4 carbons, especially acetyl, or benzoyl.
Especially preferred as final products are the compounds of formula I having the mercaptoacyl sidechain wherein Rg is hydrogen; m is one; R^ and Rg are hydrogen; Rg is methyl; and the asymmetric carbon atom to which Rg is attached is in the D-configuration.
Preferred compounds with respect to the substituents on the proline ring are those wherein R^ and R^ are independently selected from lower alkyl of 1 to 4 carbons, especially methyl or ethyl; -caj-'O or -ch2-{0 I ; and R? is hydrogen, methyl, methoxy, ’'•N ' methylthio. Cl, Br, F, trifluoromethyl, or hydroxy; or R„ X^-R^ and Xj-Rj i°^n to fotm R^ *10 /*9 ^R *10 k A /c— cx *10 I I R1O a2c 0.
CH.
RxRi° h2c' ch2 , or H2C *9^10 wherein Rg and R10 are both hydrogen or both lower alkyl of 1 to 4 carbons, especially both hydrogen or both methyl, or Rg is hydrogen and R^g is lower alkyl of 1 to 4 carbons. 48321 especially methyl, hydroxy substituted lower alkyl of 1 to 4 carbons, especially hydroxymethyl, or halo substituted lower alkyl, especially trifluoromethyl.
Most preferred compounds with respect to the substituents on the proline ring are those wherein X1 and X2 are the same especially those ..wherein Xj,-R^ and X.,-R2are m®thoxy or both ethoxy or X^R^ and X2-R2 ^θ3·η together to 0 form CH, CH_ H-C-CH I I 0 0 H2C CH, CH, /3 H-C- CH , H-C 2, , 2 S S CH_ /CH< H2?' The compounds of formula I are obtained by coupling the substituted proline or pipecolic acid of the formula 49331 - 10 (II) X1 /2 XCZ(H2C)p ^2>α ΙΟ — C-COOR I* H with an acid or its chemical equivalent of the formula (III) % R3 , r 13 R,-S- (CH) — C — COOH 5 m j R6 » wherein Rg is hydrogen, a hydrolyzahly or chemically removable protecting group to yield the product of the formula (IV) „ „ ΗΝ20 (Y,p |i ,2 X2 X (ch2’ R,-S-(CH) — C— CO— N 5 ° I C-COOR 1* 331 -11This reaction can be effected in the presence of a coupling agent such as dicyclohexylcarbodiimide or the like, or the acid can be activated by formation of its mixed anhydride, symmetrical anhydride, acid halide, active ester or use of Woodward reagent K, N-ethoxycarbonyl-2-ethoxy-l,2-dihydroquinoline or the like. For a review of the methods of acylation, see Methoden der Organishchen Chemie (Houben-Weyl), Vol. XV, part II, page 1 et seq. (1974). Preferably, the acid halide, especially the acid chloride, of formula III is reacted with the acid of formula II.
If the proline or pipecolic acid of formula II is reacted in the ester form the resulting ester product of formula IV, i.e., R is alkyl, can be converted to the free acid, i.e., R is hydrogen, by conventional means. For example, if R is ethyl this ester protecting group can be removed by saponification.
The product of formula IV is preferably isolated and purified by crystallization, e.g., by forming the dicyclohexylamine salt and then converting the salt to the free acid form by treatment with an aqueous solution of an acid, such as potassium acid sulfate.
The product of formula IV bearing the acyl group Rg-CO- can be converted to the products of formula I wherein R^ is hydrogen by conventional hydrolysis or by ammonolysis. - 12 The products of formula I wherein and R^ are other than -(CH,) -SH and R_ is 2 n 5 Ιχ I4 X. X. ^cz 1 (H2C)p -S-(CH)— Cm CO— N15 are obtained by directly oxidizing with iodine a product of formula I wherein Rg is hydrogen.
The esters of formula I wherein R is lower alkyl can be obtained from the carboxylic acid compounds, i.e., wherein R is hydrogen, by conventional esterification procedures, e.g., by esterification with a diazoalkane such as diazomethane, a l-alkyl-3-p-tolyltriazene, such as l-n-butyl-3-p-tolyltriazene, or the like.
The disubstituted prolines or pipecolic acids of formula II wherein X^-R^ and X2"R2 are the same, can be obtained by reacting an Nprotected keto compound of the formula (V) 0 II C z \ (H,C) (CH.,) Cbz — N-Cr-COOR I* H - 13 wherein Cbz represents carbobenzyloxy with an alcohol or thiol having the formula (VI) Rg-Xj-H in the presence of an orthoformate or thioformate of the formula HC(X^-R^)g and an acid such as concentrated sulfuric acid or p-toluenesulfonic acid. This reaction can be effected in an inert organic solvent such as benzene, acetic acid, ether, cyclohexane or the like, preferably with heating, e.g., at about reflux temperature.
See Buehler et al., Survey of Organic Syntheses (Wiley 6 Sons, 1977) Vol. 1, pages 516-519. The product of this reaction is the N-protected intermediate of the formula xc / \ 2C)p (CH2)q Cbz — N- C-COOR ι H The N-protected intermediate of formula VII can be treated with a molar equivalent of an alcohol or thiol of the formula 321 (VIII) according to the conditions described above to yield the intermediate (IX) R. ‘1
X. '2 wherein Rg, R^Q, and t are are defined above in the presence of an acid such as p-toluenesulfonic acid, to yield the intermediate (XII) ‘1 X.
X. '2 Cbz-N-C-COOR I* H Alternatively, the disubstituted compound 4-9321 - 16 of fonnula VII can be treated directly with a molar excess of the alcohol or thiol of formula XI to yield the intermediate of formula XII. This procedure is particularly useful when Rg and are either or both other than hydrogen.
As described above, the N-protecting group can then be removed to yield the spiro compounds of fonnula II.
As an alternative procedure, the introduction 10 of the X^-R^ and Xg-R2 3rouPs can effected later in the sequence. According to this modification, the protected keto compound of formula V is treated to remove the protecting group, e.g., with hydrogen bromide, resulting in an intermediate having the formula (XIII) II c / \ <*2C>p (CH2)q H — N--%-COOH I H which is then acylated with the acid, preferably the acid halide, of formula III to yield the compound of the fonnula 48321 - 17 (XIV) R'~ S — (CH)· I c0 (He) (CH ) .. 2, Ρ ι 2 <3 C.-COOH I* The groups and X2-R2 or the spir0 V^oup R« R-j \ Ζ -1·0 can then be introduced at this 15 Z (c,t\ X1 X2 point by the procedures described above to yield the product of formula IV.
Reference is also made to the following publications for additional illustrative methodology for producing starting materials and intermediates: U.S. Patents 4,046,889, 4,105,776, 4,154,935 and 4,116,962; Can. J. Biochem. & Physiol. 37, 584 (1959); J.A.C.S. 79, 189 (1957); J. Med. Chem. 21, 445 (1978); Aus. J. Chem. 20, 1493-1509 (1967); Buehler et al., Survey of Organic Syntheses (Wiley s Sons, 1977), Vol. 1, pages 516-519, Vol. 2 pages 461-470; Chem. Pharm. Bull., Tokyo 26, 2209 and 2217 (1978); Can. J. Chem. 47, 860 (1969); - 18 J. Amer. Chem. Soc., 8JD, 6350 (1958); Harrison et al.. Compendium of Organic Synthetic Methods, (WileyInterscience, New York, 1971), pages 449-456; J. Amer. Chem. Soc., 79, 192 (1956); Bull. Soc.
Chem., 1965(8) pages 2253-2259; J. Org. Chem. 25, p. 521-530 (1960).
The procedures illustrated therein can be utilized as general methods for the synthesis of compounds and separation of isomers which can be utilized in the invention described in this application. Additional illustrative details are found in the examples which serve as models for the preparation of other members of the group.
The compounds of this invention form basic salts with a variety of inorganic or organic bases. The salt forming ion derived from such bases can be metal ions, e.g., aluminum, alkali metal ions, such as sodium or potassium, alkaline earth metal ions such as calcium or magnesium, or an amine salt ion, of which a number are known for this purpose, for example aralkylamines like, dibenzylamine, N,N-dibenzylethylenediamine, lower alkylamines like methylamine, t-butylamine, procaine, lower alkylpiperidines like N-ethylpiperidine, cycloalkylamines, like cyclohexylamine or dicyclohexylamine, 1-adamantanamine, benzathine, or salts derived from amino acids like arginine, lysine or the like. The physiologically acceptable salts like the sodium or potassium salts can be used medicinally as described 48321 - 19 below and are preferred. These and other salts which are not necessarily physiologically acceptable are useful in isolating or purifying a product acceptable for the purposes described below, as illustrated with the dicyclohexylamine salt in the examples.
The salts are produced by reacting the acid form of the compound with a equivalent of the base supplying the desired basic ion in a medium in which the salt precipitates or in aqueous medium and then lyophilizing. The free acid form can be obtained from the salt by conventional neutralization techniques, e.g., with potassium bisulfate, hydrochloric acid, etc.
The compound of formula I wherein Rg is hydrogen, *ί, , or the disulfide type Rg-Csubstituent, especially wherein Rg is hydrogen, are useful as hypotensive agents. They inhibit the conversion of the decapeptide angiotensin I to angiotensin XI and, therefore, are useful in relieving angiotensin related hypertension. The actiqn of the enzyme renin on angiotensinogen, a pseudoglobulin in blood plasma, produces angiotensin I. Angiotensin I is converted by angiotensin converting enzyme (ACE) to angiotensin II. The latter is an active pressor substance which has been implicated as the causative agent in various forms of hypertension in various mammalian species, e.g., rats and dogs.
The compounds of this invention intervene in the angiotensinogen * (renin) ♦ angiotensin I * (ACE) * angiotensin II sequence by inhibiting angiotensin - 20 converting enzyme and reducing or eliminating the formation of the pressor substance angiotensin II.
Thus by the administration of a composition containing one, or a combination of compounds of formula I angiotensin dependent hypertension in the species of mammal suffering therefrom is alleviated. A single dose, or preferably two to four divided daily doses, provided on a basis of about 0.1 to 100 mg. per kilogram of body weight per day, preferably about 1 to 15 mg. per kilogram of body weight per day is appropriate to reduce blood pressure. The substance is preferably administered orally, but parenteral routes such as the subcutaneous, intramuscular, intravenous or intraperitoneal routes can also be employed.
The compounds of this invention can also be formulated in combination with a diuretic for the treatment of hypertension. A combination product comprising a compound of this invention and a diuretic can be administered in an effective amount which comprises (for a 70 kg. mammal) a total daily dosage of about 30 to 600 mg., preferably about 30 to 300 rag., of a compound of this invention, and about 15 to 300 mg., preferably about 15 to 200 mg. of the diuretic, to a mammalian species in need thereof. Exemplary of the diuretics contemplated for use in combination with a compound of this invention are the thiazide diuretics, e.g., chlorthiazide, hydrochlorthiazide, flumethiazide, hydroglumethiazide, benzdroflumethiazide, methchlothiazide, - 21 trichlormethiazide, polythiazide or benzthiazide, as well as ethacrynic acid, ticrynafen, chlorthalidone, furosemide, musolimine, bumetanide, triamterene, amiloride and spironolactone, and salts of such compounds.
The compounds of formula I can be formulated for use in the reduction of blood pressure in compositions such as tablets, capsules or elixirs for oral administration or in sterile solutions or suspensions for-parenteral administration. About 10 to 500 mg. of a compound or mixture of compounds of formula I is compounded with a physiologically acceptable vehicle, carrier, excipient, binder, preservative, stabilizer, flavor, etc., in a unit dosage form as called for by accepted pharmaceutical practice.
The amount of active substance in these compositions or preparations is such that a suitable dosage in the range indicated is obtained.
, Illustrative process details are set forth in the following examples for the various reactions.
These examples are preferred embodiments and also serve as models for the preparation of other compounds of this invention. The temperatures are given in degrees on the centrigrade scale and percertages are by weight. - 22 Example 1 [7(5),8S]—7—(Acetylthio)-2-methyl-l-oxopropyl]-1, 4-dioxo-7-azaspiro[4.4]nonane-8-carboxylic acid a) N-Carboben2yloxy-4-hydroxy-L-proline 26.5 g. (0.20 mole) of 4-hydroxy-L-proline and 32.8 ml. (0.23 mole) of benzyl chloroformate are reacted in 200 ml. of water and 100 ml. of acetone in the presence of 20 g. (0.02 mole) of potassium bicarbonate and 69.2 g. (0.50 mole) of potassium carbonate and worked up with 90 ml. of concentrated hydrochloric acid as described in Can.
J. Biochem. & Physiol. 37, 584 (1959) to obtain Ncarbobenzyloxy-4-hydroxy-L-proline. This product is reacted with cyclohexylamine to form the cyclohexylamine salt yield 69 g. , m.p. 193-195°. The salt (34 g.) is neutralized with N-hydrochloric acid to obtain 27 g. of free acid as a colorless glass (a]2® -70°, (o, IS in chloroform). b) N-carbobenzyloxy-4-keto-L-proline 21.5 g. (0.81 mole) of N-carbobenzyloxy-4hydroxy-L-proline is oxidized in 1.2 liters of acetone with 83 ml. of 8N chromic acid in sulfuric acid as described in J.A.C.S. 79, 189 (1957). In order to facilitate the subsequent filtration of chromium salts, 30 g. of Celite (diatomaceous earth) is added to the acetone solution before introduction of the oxidizing agent. An air stirrer is employed. The reaction mixture is filtered and the acetone filtrate is concentrated to approximately 300 ml. before diluting with 1 liter of chloroform. The solution is washed with 300 ml. of saturated sodium chloride (four tines), dried (MgSOj), filtered and the solvent evaporated to give 48321 - 23 N-carbobenzyloxy-4-keto-L-proline(22.8 g.) which is crystallized from ether (50 ml.,-hexane (150 ml.) to obtain 17.2 g. (81%) of product, m.p. 99-101°, [a]p6 +17° (c, 1% in chloroform,. c) N-Carbobenzyloxy-4,4-ethylenedioxy-L-proline A stirred mixture of 12.8 g. (0.049 mole) of N-carbobenzyloxy-4-keto-L-proline, 53 ml. (0.095 mole, of ethylene glycol, and 0.35 g. of p-toluenesulfonic acid * H^O in 1.31 1. of benzene is heated and the resulting solution is refluxed for 7 hours (water formed is collected in a Dean-Stark apparatus). After standing overnight at room temperature, the lower glycol layer is separated and the benzene solution is washed with 150 ml. of saturated sodium chloride, dried (MgSO^), and the solvent evaporated to give 14.6 g. of N-carbobenzyloxy-4,4-ethylenedioxy-Lproline as a syrupy residue. The latter is dissolved in 60 ml. of ethanol, filtered, treated with 5 g. of cydohexylaraine, and diluted with ether. On seeding and rubbing, the crystalline cydohexylamine salt separates; weight after cooling overnight, 9.0 g., m.p. 179-180° (s. 173°,. The material is reerystallized from acetonitrile, m.p. 182-184° (s. 179°), [a]p6 -21° (c, 1% in EtOH).
The cydohexylamine salt (8.4 g.) is suspended in 40 ml. of ethyl acetate, stirred, cooled, and treated with 40 ml. of IN hydrochloric acid. The layers are separated, the aqueous phase extracted with additional ethyl acetate ( 3 x 40 ml.), the combined organic layers are dried (MgSO^), and the solvent 4-9 3 21 - 24 evaporated, finally at 0.2 mm. The syrupy residue which begins to crystallize is rubbed under ether and the ether evaporated to give 6.4 g. (42%) of nearly colorless N-carbobenzyloxy-4,4-ethylene5 dioxy-L-proline, m.p. 101-103° (s. 98°), [a]26 -34° (c, 1% in CHClg). d) 4,4-Ethylenedioxy-L-proline A solution of 3.2 g. (Ο.0104 mole) of Ncarbobenzyloxy-4,4-ethylenedioxy-L-proline in 100 ml.
IQ of methanol-water (2:1) is treated with 1 g. of 5% palladium-carbon and .shaken on the Parr hydrogenator for 6 hours. The catalyst is filtered off under nitrogen, washed with methanol, and the combined filtrates evaporated, finally at 0.1 - 0.2 mm, to give 1.7 g. (94%) of colorless solid, 4,4-ethylenedioxy-L-proline; m.p. 245-247° (dec.); [a]2® -32° (c,0.5% in 1:1 MeOH-H2O). e) (7(S),8S]-7-[3-(Acetylthio)-2-methyl-l-oxopropylIl,4-dioxo-7-azaspiro[4.4]nonane-8-carboxylic acid 2Q A stirred solution of 3.2 g. of 4,4-ethylenedioxy-L-proline (0.0185 mole) in 50 ml. of water is cooled to 5° and treated portionwise with solid sodium carbonate to pH 8.5. Then while continuing stirring and cooling, a solution of 3.7 g. (0.020 mol.) of D-3-acetylthio-2-methylpropanoyl chloride in 5 ml. of ether is added portionwise while maintaining the pH at 8.5 with 25% sodium carbonate solution (about 14 ml.). After 11/4 hours, the solution is treated with 50 ml. of ethyl acetate,stirred, cooled,acidified carefully with hydrochloric acid (1:1) to pH 2.0, - 25 saturated with sodium chloride and the layers are separated. The aqueous phase is extracted with additional ethyl acetate (3 x 50 ml.), the combined organic layers are dried (MgSO^) and the solvent evaporated finally at 0.2 mm. The solid residue is rubbed under ether and the evaporation repeated to obtain 5.9 g. (100%) of [7(S), 8S]-7-[3-(acetylthio)2-methyl-l-oxopropyl]-1,4-dioxo-7-azaspiro(4.4]nonane8-carboxylic acid; m.p. 108-111°.
The product is converted to the dicyclohexylamine salt with 3.4 g. of dicyclohexylamine in 70 ml. of ethyl acetate. On seeding and rubbing, the crystalline salt precipitates and is reerystallized from 95 ml. of acetonitrile; yield 6.7 g., m.p. 187-189° (s. 184°), [25 -59° (c, 1% in EtOH).
The dicyclohexylamine salt is converted to the free acid by suspending it in ethyl acetate and treating with 75 ml. of 10% potassium bisulfate and stirring until two layers are obtained. After separating, the aqueous phase is extracted with ethyl acetate ( 4 x 75 ml.), the organic layers are combined, dried (MgSO^) and the solvent is evaporated to give 4.1 g. of colorless [7(S),8S]-7-[3-(acetylthio)2-methyl-l-oxopropyl]-1,4-dioxo-7-azaspiro[4.4]nonane8-earboxylic aoid, m.p. 120-122° (s. 117°) [a]25 -118° (c, 1% in EtOH).
Example 2 [7(S)-8S]-7-(3-Mercapto-2-methyl-l-oxopropyl)-1,4dioxo-7-azaspiro[4.4]nonane-8-carboxylic acid Argon is passed through a cold solution of 4S3S1 - 26 8.5 ml. of concentrated ammonium hydroxide in 20 ml. of water. 4.0 g. (0.013 mole) of [7{S),8S]-7[3-(acetylthio)-2-methyl-l-oxopropyl]-l,4-dioxo-7azaspiro-[4.4]nonane-8-carboxylic acid from Example le are then added and the mixture is stirred in an ice bath for a few minutes and then a room temperature under argon for two hours. The solution is treated with 30 ml. of ethyl acetate,cooled, stirred, and acidified with 16 ml. of of hydro10 chloric acid (1:1). The layers are separated, the aqueous phase is extracted with additional 30 ml. of ethyl acetate (twice),the ethyl acetate extracts are combined, dried (MgSO^) and the solvent evaporated to give [7(S),8S]-7-(3-mercapto-2-methy1-115 oxopropyl)-1,4-dioxo-7-azaspiro[4.4]nonane-8carboxylic acid as a solid residue. The product is rubbed under ether and the evaporation is repeated.
The product is then triturated with 30 ml. of hexane, cooled for one hour, filtered under argon and dried 20 in vacuo to give 2.7 g. of colorless solid [7(S),8S]-7· (3-mercapto-2-methy1-1-oxopropyl)-1,4-dioxo-7azaspiro[4.4]nonane-8-carboxylic acid, m.p. 131-133° (s. 125°), [at]*5 -66° (c, 1% in EtOH).
Example 3 (S)-l—[(3-Acetylthio)-2-methyl-l-oxopropyl)-4,4dimethoxy-L-proline a) N-Carbobenzyloxy-4,4-dimethoxy-L-proline, methyl ester A stirred solution of 7.8 g. (0.03 mole) of N-carbobenzyloxy-4-keto-L-proline from Example 1 in 4-9321 - 27 60 ml. of methanol ia treated with 96 ml. of trimethyl orthoformate, followed by 0.6 ml. of concentrated sulfuric acid and allowed to stand overnight at room temperature.
The pale yellow solution is stirred, treated with 1.5 g. of potassium carbonate, followed by 30 ml. of water and the bulk of the solvent is removed on a rotary evaporator to give a syrupy residue which is shaken with 30 ml. of water and 30 ml. of chloroform. After separating the layers the agueous phase is- extracted with additional chloroform (3 x 30 ml.) and the combined organic layers are washed with 45 ml. of saturated sodium chloride solution and dried (MgSO^). Evaporation of the solvent yields 8.4 g. (88%) of N-carbobenzyloxy-4,4-dimethoxy-L-proline, methyl ester. b) N-Carbobenayloxy-4,4-dlmethoxy-L-proline The ester (8.4 g., 0.026 mole) from part a is dissolved in 80 ml. of methanol, treated dropwise at -1° to 4° with 18 ml. (0.036 mole) of 2N sodium hydroxide kept at 0° for one hour, and at room temperature overnight. After removing about one half of the solvent on a rotary evaporator, the solution is diluted with 150 ml. of water, washed with 100 ml. of ether (wash discarded), acidified while cooling with 63 ml. of 1:1 hydrochloric acid to pH 2, and extracted with ethyl acetate (4 x 750 ml.). The combined extracts are washed with 50 ml. of saturated sodium chloride solution, dried (MgSO4), and the solvent evpaorated to give 8.0 g. of a pale yellow - 28 viscous oil. The oil is dissolved in 35 ml. ethanol, treated with 3.0 g. of cyclohexylamine in 10 ml. of ethanol and diluted to 500 ml. with ether. On seeding and rubbing, the crystalline N-carbobenzyloxy-4,45 dimethoxy-L-proline cyclohexylamine salt separated; weight after cooling overnight, 7.0 g., m.p. 157-159° (s, 151) -34° (c, 1% in EtOH). This material is recrystallized from 100 ml. of acetonitrile to give the salt as a colorless solid, m.p. 158-160° (s, 154°) [a]25 -33° (c, 1% in EtOH).
The N-carbobenzyloxy-4,4-dimethoxy-L-proline cyclohexylamine salt is suspended in 40 ml. of ethyl acetate, stirred and treated with 25 ml. of IN hydrochloric acid. When two clear layers are obtained they are separated, the aqueous phase is extracted with additional ethyl acetate (3 x 40 ml.), the combined organic layers are dried (MgSO^), and the solvent evaporated, finally at 0.2 mm and 40° to yield 7.2 g. (70%) of N-carbobenzyloxy-4,4-dimethoxy20 L-proline as a pale yellow viscous syrup. c) 4,4-Dimethoxy-L-proline A solution of N-carbobenzyloxy-4,4-dimethoxyL-proline (72 g., 0.022 mole) in 210 ml. of methanolwater (2:1) is treated with 2.3 g. of 5% palladium25 carbon and shaken on a Parr hydrogenator for 6 hours. The catalyst is filtered off under nitrogen, washed with methanol, and the combined filtrates are evaporated, finally at 0.1 - 0.2 mm., to give a partly, crystalline residue. This residue is taken up in 200 ml. of methanol and the evaporation repeated. - 29 When the solid is rubbed under ether (evaporation again repeated) there is obtained 3.6 g. (95%) of nearly colorless 4,4-diraethoxy-L-proline, m.p. 192-194° (dec.) ; [a]26 -47° (c, 1% in MeOH).
A sample crystallized from methanol-ether is colorless and melts at 197-198° (dec.);[a]26 -49° (c, 1% in MeOH). d) (S)-1-(3-(Acetylthio)-2-methyl-l-oxopropyl)-4,4dimethoxy-L-pro1ine A stirred solution of 3.3 g. (0.019 mole) of 4,4-dimethoxy-L-proline in 50 ml. of water is cooled to 5° and brought to pH 8.5 by the addition of 25% sodium carbonate solution (w/v). Then while continuing stirring and cooling, a solution of 3.8 g. (0.021 mole) of D-3-acetylthio-2-methylpropanoyl chloride in 5 ml. of ether is added portionwise while maintaining the pH at 7.5 - 8.5 by dropwise addition of 25% sodium carbonate solution. When the pH has stabilized at 8.2 - 8.4 (after about 15 minutes), stirring and cooling is continued for a total of one hour. The solution is then washed with 50 mi. of ethyl acetate (wash discarded, layered over with 50 ml. of ethyl acetate, cooled, stirred, acidified carefully with 1:1 hydrochloric acid to pH 2.0, saturated with sodium chloride, and the layers separated. The agueous phase is extracted with additional ethyl acetate (3x50 ml.), the combined organic layers are dried (MgSO^), and the solvent evaporated, finally at 0.2 mm, to give 6.7 g. of syrupy product. This syrup is treated in 70 ml. of ethyl acetate with 3.9 g. of dicyclohexylamine to give 6.5 g. 493 21 - 30 of colorless (S)-1-[3-(acetylthio)-2-methyl-l-oxopropyl]-4,4-dimethoxy-L-proline dicyclohexylamine salt in crops (3.1 g. and 3.4 g.), m.p. 158-160° (s, 145°). [α]θ6 -71° (c, 1% in EtOH).
Following recrystallization from 20 ml. of hot ethyl acetate-60 ml. of hexane, the colorless solid salt weighs 6.0 g., m.p. 158-166° (s, 155°), (α,ρ5 -69° (c, 1% in EtOH).
The dicyclohexylamine salt is converted to 10 the free acid by suspending 5.0 g. in 50 ml. of ethyl acetate, cooling and .treating with 60 ml. of 10% potassium bisulfate solution to give 2 clear layers. After separating, the aqueous phase is extracted with ethyl acetate (3 x 50 ml.), the combined organic layers are dried (MgSO^), and the solvent evaporated, finally at 0.1 - 0.2 mm. and 45° to give 4.1 g. (69%) of (S)-l-[3-(acetylthio)-2-methyl-l-oxopropyl]4,4-dimethoxy-L-proline as a viscous, almost glasslike material [a]^ -H2° (c, 1% in EtOH).
Example 4 (S)—1—(3-Mercapto-2-methyl-l-oxopropyl)-4,4-dimethoxyL-proline Argon is passed through a cold solution of 8.5 ml. of concentrated ammonium hydroxide in 20 ml. of water for 0.25 hour. The latter is then added while cooling and under a blanket of argon to 4.1 g. (0.013 mole) of (S)-l-[3-(acetylthio)-2-methyl-loxopropyl]-4,4-dimethoxy-L-proline and the mixture is swirled in an icebath until a pale yellow solution is obtained (about 15 minutes). Stirring under 4-3321 - 31 argon is continued at room temperature for an additional 2 hours, then the solution is extracted with 30 ml. of ethyl acetate (this and subsequent operations are carried out as much as possible under an argon atmosphere,. The aqueous layer is cooled, stirred, layered over with 30 ml. of ethyl acetate, and acidified portionwise with approximately 16 ml. of 1:1 hydrochloric acid. The layers are separated, the aqueous phase is extracted with additional ethyl acetate (3 x 30 ml.), the combined ethyl acetate layers are dried (MgSO^), and the solvent evaporated to give 3.5 g. (100%) of (S)-l-(3-mercapto-2methyl-l-oxopropyl)-4,4-dimethoxy-L-proline as a 25 o colorless, viscous syrup, [α]θ -72° (c, 1% in EtOH). 15 The latter (3.4 g.) is triturated with 20 ml. of ethyl acetate, rubbed, diluted with 30 ml. Of hexane, and cooled to give a colorless solid, weight 2.6 g., m.p. 108-110°, lot]-77° (c,l% in EtOH).
Example 5 (S)-1-[3-(Acetylthio)-2-methyl-l-oxopropyl]-4, 4diethoxy-L-proline a) N-Carbobenzyloxy-4,4-diethoxy-L-proline, ethyl ester Following the procedure of Example 3 (a) but substituting triethyl orthoformate for the trimethyl orthoformate and ethanol for the methanol one obtains 10.8 g. of N-carbobenzyloxy-4,4-diethoxy-Lproline, ethyl ester as a yellow oil. 4-3321 - 32 I b) N-Carbobenzyloxy-4, 4-diethoxy-L-proliites1' The crude ester from part (a) (10. ^g., 0.03 mole) is saponified with 70 ml. of IN soditjifi hydroxide according to the procedure of Example 3 (b)/, 30 ml. f.J, of ethanol is added in 10 ml. portions to ohtam a ·}, solution, to give 10.5 g. of a yellow viscous oil.
This oil is dissolved in 100 ml. of ether and treated with cyclohexylamine (3.0 g.). On seeding and rubbing, 8.3 g. of the crystalline N-carbobenzyloxy-4,4-diethoxy L-proline cyclohexylamine salt separates;^m.p. 123-126° (s. 114°) [a]26 -32° (c, 1% in ethanol).
This material is recrystallized from 20 ml. of acetonitrile to give 7.0 g. of the salt^as a colorless solid; m.p. 125-128° (s. 115°) [a]26 -31° (c, 1% in ethanol).
The N-carbobenzyloxy-4,4-diethoxy-L-proline cyclohexylamine salt is suspended in 40 ml. of ethyl acetate, stirred and treated with 20 ml. of 1 N hydrochloric acid. The layers are separated and the aqueous phase is extracted with additional ethyl acetate (3 x 40 ml.), the organic layers are combined, dried (MgSO^), and the solvent evaporated to give 5.6 g. (56%) of N-carbobenzyloxy-4,4-diethoxyL-proline as a light yellow oil. c c) 4,4-Diethoxy-L-proline A solution of the N-carbobenzyloxy-4,4-diethoxy L-proline (5.6 g., 0.017 mole) in 180 ml. of 2:1 ethanol-water is treated with 2 g. of a 5% palladium carbon catalyst and shaken under 3 atmospheres of hydrogen for six hours. The crude partly solid J - 33 product is rubbed first under ethanol, then ether, and the evaporation repeated each time to give 3 g. (91%) of nearly colorless solid 4,4-diethoxy-Lproline; m.p. 172-174° (dec.,; preceded by gradual darkening and sintering ία]35 "40° (c, 1% in methanol).
Anal. Calc'd. for C„H.,NO. » 0.25 H.O: 17 4 2 C, 52.03; H, 8.49; N, 6.74 Found: C, 52.22; H, 8.59; N, 6.69. d) (S)-1-(3-(acetylthio)-2-methyl-l-oxopropyl]-4,4diethoxy-L-proline The 4,4-diethoxy-L-proline (2.9 g., 0.014 mole) from part (c) and 3 g. (0.017 mole) of D-3-aeetylthio-2-methylpropionyl chloride dissolved in 3.5 ml. of ether are reacted in 35 ml. of water in the presence of sodium carbonate according to the procedure of Example 3 (d) to yield 5.4 g. of pale yellow viscous oil. This oily product is treated in 40 ml. of ethyl acetate with 2.6 g. of dicyclohexylamine and diluted with 60 ml. of hexane to yield in two crops 4.9 g. of (S)-l-[(3-acetylthio)-2methyl-l-oxopropyl].-4 ,4-diethoxy-L-proline dicyclohexylamine salt; m.p. 135-138° (s. 132°). Following recrystallization from 15 ml. of hot ethyl acetate45 ml. of hexane, the colorless solid salt weighs 4.2 g.; m.p. 138-140° (s. 135°), [a]26 -63° (c, 1% in ethanol).
Anal. Calc'd. for C^H^NOgS · c12H23Ns C, 61.33; H, 9.15; N, 5.30; S, 6.06 Found: C, 61.48; H, 9.55; N, 5.25; S, 5.91. 4-9321 ( - 34 The dicyclohexylamine salt is converted to -the free acid by suspending 4.2 g. in 40 ml. of ethyl acetate, cooling and treating with 40 ml. of 10% potassium bisuifate solution to give two layers.
After separating, the agueous phase is extracted with ethyl acetate (3 x 50 ml.), the combined organic layers are dried (MgSO4), and the solvent evaporated to give 3.0 g. (61%) of (S)-1-(3-(acetylthio)-2-methyll-oxopropyl )-4,4-diethoxy-L-proline as a pale yellow viscous syrup.
Example 6 (S)-4,4-Diethoxy-l-(3-Mercapto-2-methyl-1-oxopropyl)-Lproline Argon is passed through a cold solution 15 of 5.5 ml. of concentrated ammonium hydroxide in 13 ml. of water for 0.25 hour. The latter is then added while cooling under a blanket of argon to 3.0 g. (0.0086 mole) of (S)-1-[3-(acetylthio)-2-methyll-oxopropyl] -4, 4-diethoxy-L-proline and the mixture is worked up as described in Example 4 to yield 2.4 g. (92%) of (5)-4,4- diethoxy-1-(3mercapto-2-methyl-l-oxopropyl)-L-proline as a nearly colorless viscous syrup [a]2® -64°, (c, 1% in ethanol).
Anal. Calc'd. for C^gHggNOg · 0.25 HgO: C, 50.38; H, 7.64; H, 4.52; S, 10.35 Found: C, 50.68; H, 7.96; N, 4.78; S, 10.07.
Example 7 [2(S),3S]-2-[3-(Acetylthio)-2-methyl-l-oxopropyl]30 6,10-dioxo-2-azaspiro[4.5]decane-3-carboxylic acid a) N-Carbobenz yloxy-4,4-trimethylenedioxyL-proline - 35 Interaction of 8.2 g. (0.031 mole) of N-carbobenzyloxy-4-keto-L-proline and 45 ml. (0.62 mole) of 1,3-propanediol in 450 ml. of benzene in the presence of 500 mg. of p-toluenesulfonic acid gives 12.3 g. of crude viscous ester product.
This product is saponified with 70 ml. of IN sodium hydroxide to give 10.6 g. of crude N-carbobenzyloxy-4,4-trimethylenedioxy-L-proline as a yellow oil. The latter is dissolved in 40 ml. of ethanol - 400 ml. ether and treated with 3.2 g. of cyclohexylamine to yield 10.1 g. ofN-carbobenzyloxy-4,4-trimethylenedioxy-L-proline, cyclohexylamine salt; m.p. 163-165° (s. 160°), [a]26 -27° (c, 1% in ethanol). Crystallization of 9.8 g. of the salt from 300 ml. of acetonitrile yields 9.5 g. of colorless solid cyclohexylamine salt; m.p. 165-167° (s, 162°) [a]25 -27° (c, 1% in ethanol).
The cyclohexylamine salt (9.0 g.) is suspended in 40 ml. of ethyl acetate, stirred, cooled, and treated with 45 ml. of 1 N hydrochloric acid.
The layers are separated, the agueous phase extracted with additional ethyl acetate (3 x 40 ml.), the combined organic layers are dried (MgSO^), and the solvent evaporated to give 7.1 g. (75%) of glasslike N-carbobenzyloxy-4,4-triraethylenedioxy-Lproline. b) 4,4-Trimethylenedioxy-Ii-proline A solution of 7.1 g. (0.022 mole) of Ncarbobenzyloxy-4,4-trimethylenedioxy-L-proline in 200 ml. of 2:1 methanol-water is hydrogenated in - 36 the presence of 2 a. of 5% palladium- carbon catalyst to give 3.8 g. (93%) of nearly colorless 4,4-trimethylenedioxy-L-proline; m.p. 234-236° (dec.); preceded 25 O by gradual darkening and sintering; [a]^ -36 (c, 0.5% in 1:1 methanol-water).
Anal. Calc'd. for C.H.,N0.: 13 4 C, 51.33; H, 7.00; N, 7.48 Found: C, 51.42; H, 7.11; N, 7.40. c) [2(5),3S]-2-(3-(Acetylthio)-2-methyl-l-oxopropyl)10 6,10-dioxo-2-azaspiro[4,5]decane-3-carboxylic acid 4,4-Trimethylenedioxy-L-proline (3.7 g., 0.02 mole) is acylated with 4.0 g. (0.022 mole) of D-3-acetylthio-2-methylpropionyl chloride in 50 ml. of water in the presence of sodium carbonate according to the procedure of Example 1 (e) to give 7.3 g. of glass-like crude product.
The product is converted to its dicyclohexylamine salt with 3.6 g. of dicyclohexylamine in 70 ml. of ethyl acetate. On seeding and rubbing, the crystalline salt precipitates to yield 7.5 g. of dicyclohexylamine salt; m.p. 168-170° (s. 166°), [a]p6 -59° (c, 1% in ethanol). Recrystallization from 30 ml. of acetonitrile gives 6.5 g. of colorless solid salt; m.p. 169-171°,.[a]^5 _g3°f 1% in ethanol).
The dicyclohexylamine salt is converted to the free acid by suspending 6.4 g. in 75 ml. of ethyl acetate and treating with 75 ml. of 10% potassium bisulfate and stirring until two layers are obtained. After separating, the aqueous j 48321 - 37 phase is extracted with ethyl acetate (4 x 75 ml.), the organic layers are combined, dried (MgSO^), and the solvent evaporated to give 4.3 g. (67%) of glasslike [2(S),3S]-2-(3-(acetylthio)-2-methyl-l-oxopropyl]5 6,10-dioxo-2-azaspiro[4,5]decane-3-carboxylic acid. Example 8 (2(S),3S]-2-(3-Mercapto-2-methyl-l-oxopropy1)-6,10dioxo-2-azaspiro[4,5]decane-3-carboxylic acid (2 (S),3SJ-2-[3-(Acetylthio)-2-methyl-l10 oxopropyl]-6,10-dioxo-2-azaspiro[4,5]decane-3-carboxylic acid (4.3 g., 0.013 mole) is hydrolyzed with 8.5 ml. of concentrated ammonia in 20 ml. according to the procedure of Example 2 to yield 0.9 g. of colorless solid product; [a]* -64 (c, 0.54 in ethanol). An additional 0.8 g. of product is obtained by extracting the aqueous phase with chloroform; [a]25 -66°. The two crops are dissolved in chloroform, evaporated, rubbed under ether, and the evaporating repeated to yield 1.7 g. (46%) of (2(S),3S]-2-(3-mercapto-2-methyl20 1-oxopropyl)-6,10-dioxo-2-azaspiro[4,5]decane-3carboxylic acid; m.p. 169-171° (s. 167°), [a]^ -71° (c, 1% in methanol).
Anal. Calc'd. for ci2H19N°5S: C, 49.81; H, 6.62; N, 4.84; S, 11.08 Found: C, 49.67; H, 6.67; N, 4.93; S, 11.10.
Example 9 (7(S),8S]-7-[3-(Acetylthio)-2-methyl-l-oxopropyl]-7aza-l,4-dlthiaspiro(4.4]nonane-8-carboxylic acid a) N-Carbobenzyloxy-4,4-ethylenedithio-L-proline, methyl ester A stirred solution-of 3.9 g. (0.014 mole) of - 38 N-carbobenzyloxy-4-keto-L-proline, methyl ester in 60 ml. of methylene chloride is treated with 3 ml. (0.036 mole) of ethanedithiol, cooled to 8°, and treated under an argon blanket with 3 ml. (0.024 mole) of boron trifluoride etherate. After removing the cooling bath, the pale yellow solution is stirred for an additional hour and kept overnight at room temperature. The solution is stirred, treated with several pieces of crushed ice, followed by 20 ml. of water. After 30 minutes the layers are separated and the aqueous phase (50 ml.) is extracted with additional methylene chloride (3 x 30 ml.). The combined organic layers are washed with 50 ml. of saturated sodium chloride solution, dried (MgSO^), and the solvent removed on a rotary evaporator to . give 6 g. (100%) of a pale yellow oil N-carbobenzyloxy-4, 4-ethylenedithio-L-proline, methyl ester. b) N-Carbobenzyloxy-4,4-ethylenedithio-L-proline The methyl ester product from part (a) 2o (7.4 g., approximately 0.018 mole) is dissolved in 65 ml. of methanol, treated dropwise at -1° to 4° with 14.5 ml. (0.029 mole) of 2N sodium hydroxide, kept at 0° for one hour, and at room temperature overnight. After removing about half the solvent on a rotary evaporator, the solution is diluted with 125 ml. of water, washed with ether (wash discarded), acidified while cooling with 5 ml. of 1:1 hydrochloric acid to a pH of 2, and extracted with ethyl acetate (4 x 50 ml.). The combined extracts are washed with 50 ml. of saturated sodium chloride, - 39 dried (MgSO^), and the solvent evaporated to give 6 g. of a pale yellow viscous oil. Thia oil is dissolved in 25 ml. of ethanol, treated with 1.8 g. of cyclohexylamine in 5 ml. of ethanol, and diluted to 300 ml. with ether. On seeding and rubbing, the crystalline cyclohexylamine salt separates to yield after overnight cooling 5.7 g. of N-carbobenzyloxy-4 ,4-ethylenedithio-L-proline cyclohexylamine salt; m.p. 205-207° (s. 201°). Recrystallization from 50 ml. of ethanol-400 ml. ether yields 4.9 g. of colorless solid salt? m.p. 207-209° (s. 201°), [a)23 -15° (c, 1% in chloroform).
The cyclohexylamine salt (4.8 g.) is suspended in 25 ml. of ethyl acetate, stirred, and treated with 25 ml. of IN hydrochloric acid. When two clear layers are obtained, they are separated, the aqueous phase is extracted with additional ethyl acetate (3 x 25 ml.), the combined organic layers are dried (MgSO^), and the solvent evaporated to give 3.8 g. (62%) of N-carbobenzyloxy-4,4-ethylenedithio-Ii-proline as a pale yellow viscous syrup. c) 4,4-Sthylenedithio-L-proline, hydrobromide N-Carbobenzyloxy-4,4-ethylenedithio-Lproline (3.7 g., 0.011 mole) is treated with 20 ml. of hydrogen bromide in acetic acid (30 - 32%), stoppered loosely, and stirred magnetically. Mixing is difficult due to the viscosity of the starting material and the latter is broken up as much as possible with a spatula. In the meantime, the crystalline product begins to separate. Further - 40 quantities of hydrogen bromide in acetic acid are added after 15 minutes (10 ml.) and after 25 minutes (5 ml.) and stirring is continued for a total of 35 minutes. Ether (250 ml.) is added to complete precipitation of the product and after cooling for minutes the cream colored material is filtered under nitrogen, washed with ether, and dried in vacuo to give 2.7 g. of 4,4-ethylenedithio-L-proline, hydrobromide; m.p. 240-242° (dec.); sintering and o 26 o IQ darkening from approximately 200°; [α]θ -40 (c, 0.5% in 1:1 chloroform-methanol). d) [7(S),8S]-7-[3-(Acetylthio)-2-methyl-l-oxopropyl17-aza-l,4-dithiaspiro[4.4]nonane-8-carboxylic acid A stirred solution of 2.6 g. (0.0091 mole) of 4,4-ethylenedithio-L-proline, hydrobromide in ml. of vzater is cooled to- 5° and brought to pH 8.2 by the addition of 25% sodium carbonate (wt./vol.). While continuing stirring and cooling, a solution of 1.9 g. (0.01 mole) of D-3-acetylthio-22Q methylpropionyl chloride in 2.5 ml. of ether is added portionwise while maintaining the pH at 7.5 - 8.2 by the dropwise addition of 25% sodium carbonate. When the pH is stabilized at 8.2 - 8.5 (after about 15 minutes), stirring and cooling are continued for a total of one hour. The solution is then washed with 25 ml. of ethyl acetate (wash discarded), layered over with 25 ml. of ethyl acetate, cooled, stirred, acidified carefully with 1:1 hydrochloric acid to pH 2.0, saturated with 30 sodium chloride, and the layers separated. The - 41 aqueous phase is extracted with additional ethyl acetate (3 x 25 ml.), the combined organic layers dried (MgSO^), and the solvent evaporated, finally at 0.2 mm., to give 2.6 g. of syrupy product which begins to crystallize. The latter is treated in 30 ml. of ethyl acetate with 1.5 g. of dicyclohexylamine to give 3.0 g. of colorless dicyclohexylamine salt; m.p. 176-178° (s, 170°); [a]26 -55° (c, 1% in ethanol). This material is ground in a mortar under 15 ml. of acetonitrile, cooled for one hour, filtered, washed with 5 ml. of.cold acetonitrile and with ether, and dried to give 2.9 g. of dicyclohexylamine salt; m.p. 177-179° (s, 172°); [a]26 -56° (c, 1% in ethanol).
Anal. Calc'd. for C,,H1aNO.S · C,-H_,N: 19 4 12 23 C, 56.56; H, 7.98; N, 5.28; S, 18.12 Found: C, 56.21; H,8.18; H, 5.05; S, 18.00.
The above dicyclohexylamine salt is converted to the free acid by suspending 2.8 g. in 30 ml. of ethyl acetate, cooling, and treating with 30 ml. of 10% potassium bisulfate to give two clear layers. After separating, the aqueous phase is extracted with ethyl acetate (3 x 30 ml.), the combined organic layers dried (MgSO^), and the solvent evaporated, finally at 0.1 -0.2 mm and 45°, to give 2.0 g. (63%) of colorless solid [7(S),8S)-7-[3-(acetylthio)2-methyl-1-oxopropyl]-7-aza-l,4-dithiaspiro[4.4]nonane-8-carboxylic acid, m.p., 125-126° (s, 122°); [α]^ -101 (c, 1% in ethanol). . 48321 - 42 Example 10 [7 fS),8S]-7-(3-Mercapto-2-methyl-l-oxopropyl)-7-azal, 4-dithiaspiro[4.4]nonane-8-carboxylic acid Argon is passed through a cold solution of 5 3.5 ml. of concentrated ammonia in 8.5 ml. of water for 15 minutes. The latter is then added while cooling and under a blanket of argon to 1.9 g. (0.0054 mole) of [7(S),8S]-7-[3-(acetylthio)-2methyl-l-oxopropyl]-7-aza-l,4-dithiaspiro[4.4]nonane10 8-carboxylic acid and the mixture is swirled in an ice-bath until a solution is obtained. Stirring under argon is continued at room temperature for an additional two hours, then the solution is extracted with 15 ml. of ethyl acetate under an argon atmosphere. The aqueous layer is cooled, stirred, layered over with 15 ml. of ethyl acetate, and acidified portionwise with approximately 6.5 ml. of 1:1 hydrochloric acid. The layers are separated,· the aqueous phase extracted with additional ethyl acetate (3 x 15 ml.), the combined acetate layers dried (MgSO ), and the solvent evaporated to give 4 a glass-like residue which solidifies when rubbed under ether. The evaporation is repeated and the colorless product is suspended in 30 ml. of hexane, filtered and dried in vacuo to give 1.4 g. (84%) of (7(S),8S]-7-(3-mercapto-2-methyl-l-oxopropyl)-7aza-1,4-dithiaspiro[4,4]nonane-8-carboxylic acid; m. p. 116-118° (s, 105°); [a]26 -44° (c, 1% in ethanol). Anal. Calc'd. for C^^H^^NOgSg: Γ - 43 C, 42.97; Η, 5.57; Ν, 4.56; S, 31.29; SH, 100% Found: C, 42.70; Η, 5.71; Ν, 4.54; S, 31.16; SH, 100%.
Example 11 f7 (S),8 S)-7-(3-Mercapto-2-methyl-l-oxopropyl)-1,45 dioxo-7-azaspiro[4.5]decane-8-carboxylic acid a) [7 (S),8S]-7-(3-(Acetylthio)-2-methyl-l-oxopropyl)1.4- dioxo-7-azaspiro[4.5)decane-8-carboxylic acid Following the procedure of Example 1 but substituting an equivalent amount of N-carbobenzyloxy10 5-keto-L-pipecolic acid for the N-carbobenzyloxy-4keto-L-proline in part (c) and then following the procedure of parts (d) and (e) one obtains, [7(S),8 S) -7-(3-(acetylthio)-2-methyl-l-oxopropylJ 1.4- dioxo-7-azaspiro[4.5Jdecane-8-carboxylic acid.
IS b) [7(S),85)-7-(3-Mercapto-2-methyl-l-oxopropyl)1.4- dioxo-7-azaspiro[4,5)decane-8-carboxylic acid The product from part (a) is hydrolyzed with concentrated ammonia according to the procedure of Example 2 to yield [7(S),8S]-7-(3-mercapto-2-methyl20 l-oxopropyl)-l,4-dioxo-7-a2aspiro[4.5]decane-ecarboxylie acid.
Example 12 fl(S),2S)~1~(3-Mercapto-2-methyl-l-oxopropyl)-5,5dimethoxy-2-piperidinecarboxylic acid 25 a) fl(S),2S]-l-[3-(Acetylthio-2-methyl-l-oxopropyl·]5.5- dimethoxy-2-piperidlnecarboxylic acid Following the procedure of Example 3 but substituting an equivalent amount of N-carbobenzyloxy5-keto-L-pipecolic acid for the N-carbobenzyloxy-430 keto-L-proline in part (a) x>ne obtains [1(S),2SJ-144 [3-(acetylthio)-2-methy1-1-oxopropyl]-5,5-dimethoxy-2piperidinecarfaoxylic acid. b) [1(S),2S]-1-(3-Mercapto-2-methyl-l-oxopropyl)5,5-dimethoxy-2-piperidinecarboxylic acid 5 The product from part (a) is hydrolyzed with concentrated ammonia according to the procedure of Example 4 to yield [1(S),2S]-1-(3-mercapto-2-methyl1- oxopropyl) -5,5-dimethoxy-2-piperidinecarboxylic acid.
Example 13 1° [1(S),2-]-l-(3-Mercapto-2-methyl-l-oxopropyl)-4,4dimethoxy-2-piperidinecarboxylic acid a) [1(S) , 2—] — 1—[3-(Acetylthio)-2-methyl-l-oxopropyl]4,4-dimethoxy-2-piperidinecarboxylic acid Following the procedure of Example 3 but substituting an equivalent amount of N-carbobenzyloxy4-keto-2-pipecolic acid for the N-carbobenzyloxy-4keto-L-proline in part (a) one obtains [l(S),2-]-l13-(acetylthio)-2-methyl-l-oxopropyl]-4,4-diethoxy2- piperidinecarboxylic acid. b) [1 (S),2-1-1-[3-Mercapto-2-methyl-l-oxopropyl)-4, 4-dimethoxy-2-piperidinecarboxylic acid The product from part (a) is hydrolyzed with concentrated ammonia according to the procedure of Example 4 to yield [1(S),2-]-1-(3-mercapto-225 methyl-l-oxopropyl)-4,4-dimethoxy-2-piperidinecarboxylic acid. - 45 Example 14 [2(S),3S]-2-(3-Mercapto-2-methyl-l-oxopropyl)-6,10-dithia-2-azaspiro[4.5]decane-3-carboxylic acid a) [2(S),3S]-2-[3-(Acetylthio)-2-methyl-loxopropyl) -6,10-dithia-2-azaspiro[4.5]decane-3-carboxylic acid Following the procedure of Example 9 but substituting 1,3-propanedithiol for the ethanedithiol in part (a), one obtains [2(S],3S]-2-[3-(acetylthio)-2methyl-l-oxopropyl] - 6,10-dithio-2-azaspiro[4.5]decane3-carboxylic acid. b) [2 (S),3S]-2-(3-Mercapto-2-methyl-l-oxopropyl)-6,10dithia-2-azaspiro[4.5]decane-3-carboxylic acid The product from part (a) is hydrolyzed with concentrated ammonia according to the procedure of Example 10 to yield [2(S),3S]-2-(3-mercapto-2methyl-1-oxopropyl)-6,10-dithia-2-azaspiro[4.5]decane3- carboxylic acid.
Example 15 [7(S),8S]-7-(3-Mercapto-2-methyl-l-oxopropyl)-l-oxo4- thia-7-azaspiro[4.4]nonane-8-carboxyllc acid a) [7(S),8S]-7-[3-(Acetylthio)-2-methyl-l-oxopropyl]l-oxo-4-thla-7-azaspiro(4.4]nonane-8-carboxylic acid Following the procedure of Example 1 but substituting 2-mercaptoethanol for the ethylene glycol in part (c), one obtains £7(S).8S]—7—£3— (acetylthio)-2-methyl-l-oxopropyl]-l-oxo-4-thia7-azaspiro [4.4 J nonane-8-carboxylic acid. - 46 b) [7 (S) , 8S]’-7-(3-Mercapto-2-methyl-l-oxopropyl)1- oxo-4-thia-7-azaspiro[4.4]nonane-8-carboxylic acid The product from part (a) is hydrolyzed with concentrated ammonia according to the procedure of Example 2 to yield [7(S),8S]-7-(3-mercapto2- methyl-l-oxopropyl)-l-oxo-4-thia-7azaspiro[4.4]nonane-8-carboxylic acid.
Example 16 (8S)-7-[3-(Acetylthio)-2-trifluoromethyl-l-oxopropyl}10 1,4-dioxo-7-azaspiro[4,4]nonane-8-carboxylic acid (Isomers A and B) a) D,L-3-(Acetylthio)-2-trifluoromethylpropionic acid α-Trifluoromethyl acrylic acid (10 g., 0.071 15 mole) [prepared according to the procedure set forth J. Chem. Soc., 1954, p. 371] is cooled in a saltice-water bath, stirred and treated portionwise with 5.7 ml. (0.075 mole) of 97% thiolacetic acid.
After the addition, the yellow liquid is stirred in the cold for one hour, allowed to warm to room temperature, and distilled to yield 14 g. (91%) of D,L-3-(acetylthio)-2-trifluoromethylpropionic acid as a light yellow oil, b.p. 149-153°/13 mm. The material solidifies on storing in the cold. b) D,L-3-(Acetylthio)-2-trifluoromethylpropionyl chloride The D,L-3-(acetylthio)-2-trifluoromethylpropionyl acid (7 g., 0.032 mole) is treated with 18 ml. (0.25) of redistilled thionyl chloride and the mixture is refluxed for three hours. After ( - 47 removing the excess thionyl chloride on a rotary evaporator, the residue is distilled to give 6.8 g. of D,L-3-(acetylthio)-2-trifluororaethylpropionyl chloride as a pale yellow oil; b.p. 80-82°/16 mm. (8S)-7-[3-(Acetylthio)-2-trifluoromethyl-1oxopropyl]-1,4-dioxo-7-azaspiro[4.4]nonane-8-carboxylic acid (Isomers A and B) 4,4-Ethylenedioxy-L-proline (2.4 g., 0.014 mole) is reacted with 3.4 g. (0.014 mole) of D.L-310 (acetylthio)-2-trifluoromethylpropionyl chloride in 40 ml. of water in the presence of sodium carbonate according to the procedure of Example 1 (e) to yield 4.5 g. of nearly colorless solid product; m.p. 126-145° (s. 115°), [a]25 -34° (c, 1% in ethanol).
The mixture of diastereoisomers (4.2 g.) is suspended in 45 ml. o.f ether, stirred for two hours, cooled for 20 minutes, and the undissolved solid is filtered, washed with cold ether, and air dried to yield 2.7 g. of product; m.p. 166-172° (s. 140°), [a]p -62 (c» 1* in ethanol). The material is then ground in a mortar under 25 ml. of ether, filtered after 15 minutes, washed with some ether, and again airdried to yield 2.1 g. of product; m.p. 172-177° (s. 143°). Following crystallization from 11 ml. of boiling isopropanol and cooling overnight, 1.55 g. of colorless (8S)-7-[3-(acetylthio)-2trifluoromethyl-l-oxopropyl]-1,4-dioxo-7-azaspiru [4.4]nonane-8-carboxylic acid, isomer A is obtained; m.p. 192-194° (s, 183°), [a]25 -32° (c, 1% in ethanol).
A sample is reerystallized from isopropanol; m.p. essai - 48 193-195° (s, 184°), [a]25 -134° (c, 1% in ethanol).
Isomer B is obtained by combining the above ether and isopropanol filtrates and removing the solvents under reduced pressure to give 2.2 g. of a pale yellow solid; m.p. 108-109° (s, 95°); [a]25 + 30° (c, 1% in ethanol). This material is purified by crystallization from 6 ml. of isopropanol to give 1.2 g. of nearly colorless solid; m.p. 153-155° (s, 130°), [ct]25 +40° (c, 1% in ethanol). After crystallization from ml. of ethyl acetate -6 ml. of hexane, 1.1 g. of (8S)-7-[3-(acetylthio,-2trifluoromethyl-l-oxopropyl]-l,4-dioxo-7-azaspiro [4.4]nonane-8-carboxylic acid, isomer B; m.p. 153-155° (s, 141°), [a]25 +41° (c, 1% in ethanol) is obtained.
Example 17 (8S) -7-(3-Mercapto-2-trifluoromethyl-l-oxopropyl)-1,4dioxo-7-azaspiro[4.4]nonane-8-carboxylic acid, Isomer A Isomer A product from Example 16 (1.45 g., 0.0039 mole) is hydrolyzed with 2.5 ml. of concentrated ammonia in 6 ml. of water over a period of one hour as described in Example 2 to yield 1.25 g. (97%, of colorless (8S)-7-(3-mercapto-2-trifluoromethy1-1oxopropyl ) -1,4-dioxo-7-azaspiro[4.4]nonane-8carboxylic acid, isomer A, as a glass-like product, [ct]25 -61° (c, 1% in ethanol). TLC:R^ 0.40 (95:5:5 methylene chloride -methanol - acetic acid; vis. SH reagent, PMA and heat). c · - 49 Anal. Calc'd. for C^H^FgNOgS: C, 40.12; H, 4.28; N, 4.25; S, 9.74; F, 17.31 Found: C, 40.10, H, 4.43; N, 4,51; S, 9.63; F, 17.10.
The above acid is dissolved in ethyl acetate and treated with 1-adamantanamine to yield the 1adamantanamine salt; m.p. 213-215° (dec.), [oj25 -47° (c, 1% in methanol).
Example 18 (8S)-7-(2-Mercapto-2-trifluoromethyl-l-oxopropyl)-l,410 dioxo-7-azaspiro[4.4Inonane-8-carboxylic acid, Isomer B Isomer B product from Example 16 (1.05 g., 0.0028 mole) is hydrolyzed with 2 ml. of concentrated ammonia in 5 ml. of water according to the procedure described in Example 2 to yield 0.9 g. (97%) of (83)-7(3-mercapto-2-trifluoromethyl-l-oxopropyl)-1,4-dioxo-7azaspiro[4.4]nonane-8-carboxylic acid, Isomer B as a pale yellow viscous syrup; [a]25 -16° (c, 1% in ethanol). The material sets to a waxy solid;m.p.61-64° (s .55°) Anal. Calc'd. for: CUH14F3NO5S · 0.25 HgO: C, 39.58; H, 4.38; N, 4.20; S, 9.61; F, 17.01 Found: C, 39.60; H, 4.28; N, 4.26; S, 9.62; F, 16.89.
Exanple 19 1- [3- (Acetylthio)-2-trifluorotnethyl-l-oxopropyl]-4,425 dimethoxy-L-proline, Isomers A and B Following the procedure of Example 16 but substituting 4,4-dimethoxy-l-proline for the 4,4ethylenedioxy-L-proline in part (c), one obtains 1[3-(acetylthio)-2-trifluoromethyl-l-oxopropyl]-4,43Q dimethoxy-L-proline as a racemic mixture. The . 49321 Λ · - 50 individual isoners can be separated as taught in Example 16.
Example 20 1-(3-Mercapto-2-trifluoromethyl-l-oxopropyl)-4,4-di5 methoxy-L-proline, Isomer A and Isomer B Each individual isomer product from Example 19 is hydrolyzed with concentrated ammonia according to the procedure of Example 4 to yield 1-(3-mercapto-2trifluoromethyl-l-oxopropyl)-4,4-dimethoxy-L10 proline,isomer A and 1-(3-mercapto-2-trifluoromethy 1-1-oxopropyl)-4,4-dimethoxy-L-proline, isomer B.
Example 21 [7(S),8S]-7-(3-Mercapto-2-mereaptomethyl-l-oxopropyl)1,4-dioxo-7-azaspiro[4.4]nonane-8-carboxylic acid 15 a) [7(S),8S]-7-[3-(Acetylthio)-2-(acetylthiomethyl)1-oxopropyl] -1,4-dioxo-7-azaspiro[4.4]nonane-8carboxylic acid Following the procedure of Example 1 but substituting D-2-acetylthiomethyl-3-acetylthiopro2o pionyl chloride for the D-3-aeetylthio-2-methylpropioxyl chloride in part (e), one obtains [7(S),8S]-7-[3(acetylthio)-2-(acetylthiomethy1)-1-oxopropyl]-1,4dioxo-7-azaspiro[4.4]nonane-8-carboxylic acid. b) [7(S),8(S)1-7-(3-Mercapto-2-mercaptomethyi-l25 oxopropyl)-1,4-dioxo-7-azaspiro[4.4]nonane-8carboxylic acid The product from part (a) is hydrolyzed with concentrated ammonia according to the procedure of Example 2 to yield [7(S),8S]-7-(3-mercapto-23q mercaptomethyl-l-oxopropyl)-1,4-dioxo-7-azaspiro49321 - 51 [4.4]nonane-8-carboxylic acid.
Example 22 (S)-1-(3-Mercapto-2-mercaptomethyl-l-oxopropyl)4,4-dimethoxy-L-proline a) (S)-l-[3-(Acetylthio)-2-(acetylthiomethyl)-1-oxopropyl I-4,4-dimethoxy-L-proline Following the procedure of Example 3 but substituting D-2-acetylthiomethyl-3-acetylthiopropionyl chloride for the D-3-acetylthio-2methylpropionyl chloride in part (d), one obtains (S)-l-[3-(acetylthio)-2-(acetylthiomethyl)-1oxopropyl]-4,4-dimethoxy-L-proline. b) (S)-1-(3-Mercapto-2-mercaptomethyl-l-oxopropyl)4,4-dimethoxy-L-proline The product from part (a) is hydrolyzed with concentrated ammonia according to the procedure of Example 4 to yield (S)-l-(3-mercapto-2-mercaptomethyl-l-oxopropyl)-4,4-dimethoxy-L-proline.
Example 23 (8S)-7-(3-Mercapto-2-methylthio-l-oxopropyl)-l>4dioxo-7-azaspiro[4.4]nonane-8-carboxylic acid a) 3-(Acetylthio)-2-(methylthio)propionic acid 12.5 g. (0.094 mole) of methyl-2-(methylthio)[prepared from methyl 2-chloroacrylate according to the procedure of Gundesmann et al., Chemische Berichte 94, 3254 (1916)] is stirred with IN aqueous sodium hydroxide (94 ml.) with ice cooling.
The mixture is allowed to warm to ambient temperature, then stirred for five hours. The resulting solution is washed with ether, then acidified to pH 2 with 40321 - 52 concentrated hydrochloric acid. The solid precipitate is extracted into methylene chloride, and the solution is washed with saturated sodium chloride and the solvent evaporated. The solid residue, 2-(methylthio) acrylic acid; m.p. 70-75°, is used immediately in the following reaction.
Equimolar amounts of 2-(methylthio)acrylic acid and thiolacetic acid are mixed under argon and stirred at 80° for several hours to yield 3-(acetylthio)-210 (methylthio)propionic acid. b) 3-(Acetylthio)-2-(methylthio)propionic acid chloride The 3-(acetylthio)-2-(methylthio)propionic acid is refluxed in thionyl chloride for two hours. The reaction mixture is distilled to remove excess thionyl chloride and the product is distilled in vacuo to yield 3-(acetylthio)-2-(methylthio)propionic acid chloride. c) (8S) —7—[3-(Acetylthio)-2-methylthio-l-oxopropyl]~ 1,4-dioxo-7-azaspiro[4.4]nonane-8-carboxylic acid 4,4-Ethylenedioxy-L-proline is reacted with 3(acetylthio)-2-(methylthio)propionic acid chloride according to the procedure of Example 1 (e) to yield (8S)-7-[3-(acetylthio)-2-methylthio-l-oxopropyl]-l,4dioxo-7-azaspiro[4.4]nonane-8-carboxylic acid. d) (8S)-7-(3-Mercapto-2-methylthio-l-oxopropyl)-1, 4-dioxo-7-azaspiro[4.4]nonane-8-carboxylic acid The product from part (c) is treated with concentrated ammonia according to the procedure of Example 2 to yield (8S)-7-(3-mercapto-2-methylthio-l30 oxopropyl)-1,4-dioxo-7-azaspiro[4.4]nonane-8 48321 f - 53 carboxylic acid.
Example 24 1-(3-Mercapto-2-methylthio-l-oxopropyl)-4,4dimethoxy-L-proline a) 1-[3-(Acetylthio)-2-methylthio-l-oxopropyl]-4,4dimethoxy-L-proline 4.4- Dimethoxy-L-proline is reacted with 3(acetylthio)-2-(methylthio)propionic acid chloride according to the procedure of Example 3(d) to yield 1-[3- ( acetylthio)-2-methylthio-l-oxopropyl]-4,4dimethoxy-L-proIine. · b) 1-(3-Mercapto-2-methylthio-l-oxopropyl)-4,4dimethoxy-L-proline The product from part (a) is hydrolyzed with 15 concentrated ammonia according to the procedure of Example 4 to yield 1-(3-mercapto-2-methylthio-l-oxopropyl)-4,4-dimethoxy-L-proline.
. Example 25 (8S)-7-(3-Mercapto-l-oxopropyl)-l,4-dioxo-7-azaspiro20 [4.4]nonane-8-carboxylic acid a) (8S)-7- [3-(Acetylthio)-1-oxopropyl]-l,4-dioxo-7azaspiro[4.4]nonane-8-carboxylic acid 4.4- Ethylenedioxy-L-proline is reacted with 3-acetylthiopropionyl chloride according to the procedure of Example 1 (e) to yield (8SJ-7-[3-(acetylthio) -1-oxopropyl ]-1,4-dioxo-7-azaspiro[4.4]nonane-8oarboxylic acid. 8 3 21 - 54 b) (8S)-7-(3-Mercapto-l-oxopropyl)-1,4-dioxo-7azaspiro [4.4]nonane-8-carboxylic acid The product from part (a) is hydrolyzed with concentrated ammonia according to the procedure of Example 2 to yield (8S)-7-(3-mercapto-l-oxopropyl)1,4-dioxo-7-azaspiro[4.4]nonane-8-carboxylic acid.
Example 26 1-(3-Mercapto-l-oxopropyl)-4,4-dimethoxy-L-proline a) 1-[3-(Acetylthio)-1-oxopropyl]-4,4-dimethoxy-L10 proline 4.4- Dimethoxy-L-proline is reacted with 3- acetylthiopropionyl chloride according to the procedure of Example 3 (d) to yield 1-[3-(acetylthio)1-oxopropyl]-4,4-dimethoxy-L-proline. b) 1-(3-Mercapto-l-oxopropyl)-4,4-dimethoxy-Lproline The product from part (a) is hydrolyzed with concentrated ammonia according to the procedure of Example 4 to yield 1-(3-roercapto-l-oxopropyl)-4,420 dimethoxy-L-proline, Example 27 (8S) —7— (4-Mercapto-l-gxobutyl)-l,4-dioxo-7-azaspiro[4.41 nonane-8-carboxylic acid a) (8S)-7-[4-(Acetylthio)-l-oxobutyl]-l,4-dioxo-725 azaspiro[4.4]nonane-8-carboxylic acid 4.4- Ethylenedioxy-L-proline is reacted with 4- acetylthiobutyroyl chloride according to the procedure of Example 1 (e) to yield 8(S)—7—[4— (acetylthio)-l-oxobutyl]-1,4-dioxo-7-azaspiro[4.4]30 nonane-8-carboxylic acid. ( - 55 b)(8S)-7-(4-Mercapto-l-oxobutyl)-l,4-dloxo-7-azaspiro[4.4]nonane-8-carboxylic acid The product from part (a) is hydrolyzed with concentrated ammonia according to the pro5 cedure of Example 2 to yield (8S)-7-(4-mercapto-loxobutyl)-1,4-dioxo-7-azaspiro[4.4]nonane-8carboxylic acid.
Example 28 1-(4-Mercapto-l-oxobutyl)-4,4-dimethoxy-L-proline 10 a) 1-[4-(Acetylthio)-1-oxobutyl]-4,4-dimethoxyL-proline 4.4- Diraethoxy-L-proline is reacted with 4-acetylthiobutyroyl chloride according to the procedure of Example 3 (d) to yield 1-[4-(acetylthio,15 1-oxobutyl]-4,4-dimethoxy-L-proline. b) 1-(4-Mercapto-l-oxobutyl)-4,4-dimethoxy-Lproline The product from part (a) is hydrolyzed with concentrated ammonia according to the procedure of Example 4 to yield 1-(4-mercapto-l-oxobutyl)-4,4dimethoxy-L-proline.
Example 29 (85)-7-(2-Mercapto-l-oxoethyl)-l,4-dioxo-7-azaspiro[4.4]nonane-8-carboxylic acid a) (8S)-7-[2-(Acetylthio)-1-oxoethyl]-l,4-dioxo-7azaspiro[4.4]nonane-8-carboxylic acid 4.4- Ethylenedioxy-L-proline is reacted with acetylthioacetyl chloride according to the procedure of Example 1 (e) to yield (8S)-7-[2-(acetylthio)30 1-oxoethyl]-1,4-dioxo-7-azaspiro[4.4]nonane-84-8 3 21 ( - 56 carboxylic acid. b) (83)-7-(2-Mercapto-l-oxoethyl)-1,4-dioxo-7azaspiro[4.4]nonane-8-carboxylic acid The product from part (a) is hydrolyzed 5 with concentrated ammonia according to the procedure of Example 2 to yield (SS)-7-(2-mercapto-l-oxoethyl)1.4- dioxo-7~azaspiro[4.4]nonane-8-carboxylic acid.
Example 30 1-(2-Mercapto-l-oxoethyl)-4,4-dimethoxy-L-proline 10 a) 1-(2-(Acetylthio)-1-oxoethyl)-4,4-dimethoxyL-proline 4.4- Dimethoxy-L-proline is reacted with acetylthioacetyl chloride according to the procedure of Example 3 (d) to yield 1-[2-(acetylthio)-115 oxoethyl]-4,4-dimethoxy-L-proline. b) 1-(2-Mercapto-l-oxoethyl)-4,4-dimethoxy-L. proline The product from part (a) is hydrolyzed with concentrated ammonia according to the procedure of Example 4 to yield 1-(2-mercapto-l-oxoethyl)-4,4dimethoxy-L-proline.
Example 31 (8S)-7-(3-Mercapto-2,2-dimethy1-1-oxopropyl)-1,4dioxo-7-azaspiro[4.4]nonane-8-carboxylic acid 25 a) (8S)-7-[3-(Acetylthio)-2,2-dimethyl-l-oxopropyl)1.4- dioxo-7-azaspiro[4.4]nonane-3-carboxylic acid 4.4- Ethylenedioxy-L-proline is reacted with 3-acetylthio-2,2-dimethylpropionyl chloride according to the procedure of Example 1 (e) to yield (8S)-730 [3-(acetylthio)-2,2-dimethyl-l-oxopropyl]-1,449331 - 57 dioxo-7-azaspiro[4.4]nonane-8-carboxylic acid. b) (8S)-7-(3-Mercapto-2,2-dimethyl-l-oxopropylΙΙ, 4-dioxo-7-azaspiro [4. 4]nonane-8-carboxylic acid The product from part (a) is hydrolyzed with concentrated ammonia to yield (8S)-7-(3-mercapto2,2-dimethy1-1-oxopropyl)-1,4-dioxo-7-azaspiro[4.4]nonane-8-carboxylic acid.
Example 32 1-(3-Mercapto-2,2-dimethyl-l-oxopropyl)-4,4-dimethoxyL-proline a) 1-[3-(Acetylthio)-2,2-dimethyl-l-oxopropyl]-4,4dimethoxy-L-proline 4.4- Dimethoxy-L-proline is reacted with 3-acetylthio-2,2-dimethylpropionyl chloride according to the procedure of Example 3 (d) to give 1-[3(acetylthio)-2,2-dimethyl-l-oxopropyl]-4,4-dimethoxyL-proline. b) 1-(3-Mercapto-2,2-dimethyl-l-oxopropyl)-4,4dimethoxy-L-proline The product from part (a) is hydrolyzed with concentrated ammonia according to the procedure of Example 4 to give 1-(3-mercapto-2,2-dimethyl-loxopropyl) -4,4-dimethoxy-L-proline.
Example 33 [7(S),8S]-7-(3-Mercapto-2-ethyl-l-oxopropyl]-l,4dloxo-7-azaspiro[4.4Inonane-8-carboxylic. acid a) [7(s),8SI-7-[3-(Acetylthio)-2-ethyl-l-oxopropyl]l,4-dioxo-7-azaspiro[4.4]nonane-8-carboxylic acid 4.4- Ethylenedioxy-L-proline is reacted with D-3-acetylthio-2-ethylpropionyl chloride according 4S32£ to the procedure of Example 1 (e) to give [7(S),8S]7-[3-(acetylthio)-2-ethy1-1-oxopropyl]-l,4-dioxo-7azaspiro[4.4]nonane-8-carboxylic acid. b) [7(S),8S]-7-(3-Mercapto-2-ethy1-1-oxopropyl)-1,45 dioxo-7-azaspiro(4.4]nonane-8-carboxylic acid The product from part (a) is hydrolyzed with concentrated ammonia according to the procedure of Example 2 to give [7(S),8S]-7-(3-mercapto-2-ethyl-loxopropyl)-1,4-dioxo-7-azaspiro[4.4]nonane-810 carboxylic acid.
Example 34 (S)-1-(3-Mercapto-2-ethyl-l-oxopropyl-4,4-dimethoxyL-proline a) (S)—1—[3-(Acetylthio)-2-ethyl-l-oxopropyl]-4,415 dimethoxy-L-proline 4,4-Dimethoxy-L-proline is reacted with D-3acetylthio-2-ethylpropionyl chloride according to the procedure of Example 3 (d) to give (S)-l-[3-{acetylthio )-2-ethyl-l-oxopropyl]-4,4-dimethoxy-L-proline. b) (S) —1—(3-Mercapto-2-ethy1-1-oxopropyl)-4,4dimethoxy-L-proline The product from part (a) is hydrolyzed with concentrated ammonia according to the procedure of Example 4 to give (S)-1-(3-raercapto-2-ethyl-l25 oxopropyl)-4,4-dimethoxy-L-proline. - 59 Example 35 [8S] -7- (3-Mercapto-2-trifluorpmethvl-l-oxopropyl)-7-aza-l,4-dithiaspiro[4.41nonane-8carboxylic acid a) 3- [[(4-Methoxy)phenylmethyl]thio]-2-trifluoromethylpropionyl chloride A neat mixture of 1-trifluoromethylacrylic acid (3.9 g.) and 4-methoxyben2ylthiol (4.3 g.) is stirred at 100-110° for one hour. The mixture is allowed to cool to room temperature and the solid is recrystallized from cyclohexane to yield 3-[[(4methoxy)phenylmethyl]thio]-2-trifluoromethylpropionic acid; m.p. 72-74°.
Treatment of this acid with thionyl chloride yields 3-[[(4-methoxy)phenylmethyl]thio]-2-trifluoromethy lpropionyl chloride. b) C8S]-7-(3-f((4-Methoxy)phenylmethyllthio1-2trifluoromethy1-1-oxopropyl]-7-aza-l,4-dithiaspiro[4.4]nonane-8-carboxylic acid The 3-[[(4-methoxy)phenylmethy1]thio]-2trifluoromethyl propionyl chloride from part (a) is reacted with 4,4-ethylenedithio-L-proline according to the procedure of Exanple 9 (d) to yield [8SJ7-[3-[[(4-methoxy)phenylmethyl]thio]-2-trifluoromethyl1-oxopropyl]-7-aza-l,4-dithiaspiro[4.4]nonane-8carboxylic acid. cj [8SJ-7- (3-Mercapto-2-trifluoromethyl-loxopropyl)-7-aza-l,4-dithiaspiro[4.4]nonane-8carboxylic acid The product from part (b) is mixed with tri- 60 fluoroacetic acid and anisole under nitrogen. The solvents are removed under vacuum to yield as a residue [8S]—7—(3-mercapto-2-trifluoromethyl-loxopropyl)-7-aza-l,4-dithiaspiro[4.4]nonane-8-carboxylic acid.
Example 36 [8S]-7-(3-Mercapto-2-methylthio-l-oxopropyl)-7aza-1,4-dithiaspiro[4.4]nonane-8-carboxylicacid a) 3- [ [(4-Methoxy)phenylmethyl]thio]-2-methyIthio10 propionyl chloride 3- [ [ (4-Methoxy)phenylmethyl]thio]-2-methylthiopropanoic acid prepared according to the procedure of Example 10 in U.S. Patent 4,116,962 is treated with thionyl chloride to yield 3-[[(4-methoxy)phenylmethyl]15 thio]-2-methylthiopropionyl chloride. b) [8S] -7- [3- [ [ (4-Methoxy)phenylmethyl]thio]-2methylthio-l-oxopropyl]-7-aza-l,4-dithiaspiro[4.4]nonane-8-carboxylic acid The 3- [ [ (4-methoxy)phenylmethyl]thio]-220 methylthiopropionyl chloride from part (a) is reacted with 4,4-ethylenedithio-L-proline according to the procedure of Example 9 (d) to yield [8SJ-7[3-[[(4-methoxy)phenylmethyl]thio]-2-methylthio-loxopropyl]-7-aza-l,4-dithiaspiro[4.4 J nonane-825 carboxylic acid. c) [8S1-7-(3-Mercapto-2-methylthio-l-oxopropyl)-7-aza-l,4-dithiaspiro[4.4]nonane-8-carboxylic acid The product from part (b) is mixed with tri30 fluoroacetic acid and anisole under nitrogen. The r · - 61 solvents are removed under vacuum to yield as a residue [8SJ-7-(3-mercapto-2-methylthio-l-oxopropyl)-7-aza-l,4-dithiaspiro[4.4]nonane-8carboxylic acid.
Example 37 [7(S),8S1-7-(3-Mercapto-3-methyl-l-oxopropyl)-l,4dioxo-7-a2aspiro[4.4]nonane-8-carboxylic acid a) [7(S),8S)-7-[3-(Acetylthio)-3-methyl-loxopropyl]-1,4-dioxo-7-azaspiro[4.4]nonane-81° carboxylic acid 4.4- Ethylenedioxy-L-proline is reacted with D-3-acetylthio-3-methylpropionyl chloride according to the procedure of Example 1 (e) to yield [7(S),8S]7- (3-(acetylthio)-3-methyl-l-oxopropyl]-1,4-dioxo15 7-azaspiro[4.4]nonane-8-carboxylic acid. b) [7(S),8S]-7-(3-Mercapto-3-methyl-l-oxopropyl)-l, 4-dioxo-7-azaspiro[4.4)nonane-8-carboxylic acid The product from part (a) is hydrolyzed with concentrated ammonia according to the procedure of Example 2 to give [7(S),8S]-7-(3-mercapto-3methyl-l-oxopropyl)-1,4-dioxo-7-azaspiro[4.4]nonane8- carboxylic acid.Example 38 (S)-l-(3-Mercapto-3-methyl-l-oxopropyl)-4,4-dimethoxy25 L-proline a) (S)-l-[3-(Acetylthio)-3-methyl-l-oxopropyl)-4,4dimethoxy-L-proline 4.4- Dimethoxy-L-proline is reacted with D-3acetylthio-3-methylpropionyl chloride according to the procedure of Example 3 (d) to yield (S)-l-[3-(acetyl48321 3 S2i c thio)-3-methyl-l-oxopropyl)-4,4-dimethoxy-L-proline. b) (S)—1—(3-Mercapto-3-methyl-l-oxopropyl-4,4dimethoxy-L-proline The product from part (a) is hydrolyzed with 5 concentrated ammonia according to the procedure of Example 4 to yield (S)-1-(3-mercapto-3-methyl-loxopropyl)-4,4-dimethoxy-L-proline.
Example 39 1-(3-Mercapto-l-oxopropyl)-4,4-dimethylthio-L-proline a) 4-Keto-L-proline, hydrobrdmide To 4.0 g. (0.015 mole) of N-carbobenzyloxy-4keto-L-proline are added 20 ml. of hydrogen bromide in acetic acid (30-32%). The mixture is frequently swirled over a period of eight minutes. At the end of this period (effervescence has stopped), the yellow-orange solution is layered over with 25° of ether, triturating the gummy product. The ether is discarded and the resulting tacky solid is triturated with fresh ether and finally with 50 ml. of acetoni20 trile to give 4-keto-L-proline, hydrobromide as a crystalline solid weighing 2.7 g. (85%), m.p. 153-155° (dec.,), [a]26 -49° (c, 1% in water). b) 1-(3-(Acetylthio-l-oxopropyll-4-oxo-L-proline A stirred solution of 4.1 g. (0.0195 mole) of 4-keto-L-proline, hydrobromide in 50 ml. of water is cooled to 5° and treated portionwise with solid sodium carbonate (foaming is controlled by adding a few drops of ether) to pH 8.0 (approx. 2 g. required). Then while continuing stirring and cooling, a solution of 3.5 g. (0.012 mole) of 3-acetylthiopropanoyl chloride - 63 In 5 ml. of ethyl acetate is added portionwise by means of a pipette while maintaining the pH at 7.0 8.0 by dropwise addition of 254 (w/v) sodium carbonate solution (about 10 ml.,. After about 10 minutes the pH stabilizes at 8.0 - 8-.4. After continued stirring and cooling for a total of 1 hour, the solution is washed with ethyl acetate (2 x 50 ml.), layered over with 50 ml. of ethyl acetate, stirred, cooled, acidified carefully with concentrated hydrochloric acid to pH 2.0, saturated with sodium chloride, and the layers are separated. The aqueous phase is extracted with additional ethyl acetate (3 x 50 ml.), the combined organic layers dried (MgSO^) and the solvent evaporated, finally at 0.2 mm. to give 4.8 g. of a yellow-orange glass-like residue. This residue is dissolved in 35 ml. of ethyl acetate and treated with a solution of 3.5 g. of dicyclohexylamine in 5 ml. of ethyl acetate. On seeding and rubbing, crystalline 1-[3-(acetylthio-l-oxopropyl)]-4-oxo-L20 proline dicyclohexylamine salt separated, weight after cooling overnight, 2.7 g. (nearly colorless), m.p. 191-193° (dec.), [α]2δ -24° (c, 1% in CHClj).
This dicyclohexylamine salt is converted to the free acid using potassium bisulfate as described in Example 1 (e) to give 3.7 g. of 1-[3-(acetylthio)-1oxopropyl]-4-oxo-L-proline as a pale yellow glasslike solid. c) 1-(3-(Acetylthio)-1-oxopropyl]-4,4-dimethylthio-Lproline The 1-(3-(acetylthio)-1-oxopropyl]-4-oxo-L49321 Ί - 64 proline is reacted with methylthiol according to th© procedure of Example 9 (a) to yield 1-[3-(acetylthio)-1 oxopropyl1-4,4-dimethylthio-L-proline. d) 1-(3-Meroapto-1-oxopropyl)-4,4-dimethyIthio-L5 proline The product from part (a) is hydrolyzed with concentrated ammonia according to the procedure of Example 2 to yield 1-(3-mercapto-l-oxopropyl)-4,4dimethylthio-L-proline.
Example 40 [2(S),3S]-2-(3-Mercapto-2-methyl-l-oxopropyl)-8,8dimethyl-6,10-dioxo-2-azaspiro[4.5]decane-3-carboxylic acid a) (2(5),3SJ-2- [3-(Acetylthio)-2-methyl-l-oxopropyll15 8,8-dimethyl-6,10-dioxo-2-azaspiro[4.5)decane-3carboxylic acid Utilizing the procedure of Example 1 but substituting 2,2-dimethyl-l,3-propanediol for the ethylene glycol in part (c), one obtains [2(S),3S]-220 [3-(acetylthio)-2-methyl-l-oxopropyl]-3,8-dimethylS,lO-dioxo-2-azaspiro[4.5]decane-3-carboxylic acid. b) [2(S),3S]-2-(3-Mereapto-2-methyl-l-oxopropyl)8,8-dimethyl-6,10-dioao-2-azaspiro[4.5]decane-3-carboxylic acid The product from part (a) is hydrolyzed with concentrated ammonia according to the procedure of Example 2 to yield [2(S),3S]-2-(3-mercapto-2-methyl1-oxopropyl)-8,8-dimethyl-6,10-dioxo-2-azaspiro[4.5]deoane-8-oarboxylic acid. Ί " 65 Example 41 [7(S),851-7-(3-mercapto-2-methyl-l-oxopropyl)-1,4dioxo-7-azaspiro(4,4]nonane-2-methyl-8-carboxylic acid a) tt-Carbobenzyloxy-4,4- (l-methylethylenedloxy)-L5 proline, methyl ester A stirred mixture of 8 g. (0.025 mole) of N-carbobenzyloxy-4,4-dimethoxy-L-proline, methyl ester, from Example 3 a, 2.4 g. (0.032 mole) of 1,2propanediol, 0.4 g. of p-toluenesulfonic acid monohydrate, and 400 ml. of toluene is heated to reflux (110-112°). The rate of reflux is regulated so that solvent slowly distills by means of a Dean-Stark tube into a graduated cylinder. When 80 ml. of solvent are collected an equal volume of fresh solvent is added.to the reaction flask through an addition funnel. This procedure of removing and replacing 80 ml. of solvent is repeated four times during a total reflux period of 1.25 hours.
After standing overnight, the mixture is washed with water. (2 x 100 ml.), the combined washes are back extracted with 100 ml. of toluene, the combined organic layers are dried (MgSO^), and the solvent is removed on a rotary evaporator, finally at 0.2 mm., to give 8.2 g. (99%) of N-carbobenzyloxy25 4,4-(1-methylethylenedioxy)-L-proline, methyl ester as a yellow viscous oil. b) N-Carbobenzyloxy-4,4-(1-methylethylenedioxy)-Lproline The crude methyl ester product from part (a) (8.2 g., 0.025 mole) is dissolved in 80 ml. of methanol, 48321 - 66 treated dropwise at -1° to 4° with 18 ml.' (0.036 mole) of 2N sodium hydroxide, kept at 0° for one hour, and at room temperature overnight. After removing about half of the solvent on a rotary evaporator, the solution is diluted with 150 ml. of water, washed with 100 ml. of ether (wash discarded), acidified while cooling with 6.3 ml. of 1:1 hydrochloric acid to pH 2, and extracted with ethyl acetate (4 x 75 ml.). The combined extracts are washed with 50 ml. of saturated sodium chloride, dried (MgSO^), and the solvent evaporated to give 8 g. of a red-orange viscous oil. This oil is dissolved in 50 ml. of acetonitrile, warmed, stirred, and treated with 3.8 g. of 1-adamantanamine. The solid salt rapidly separates. After cooling overnight, the material is filtered, washed with cold acetonitrile and with ether, and dried in vacuo to yield 10.3 g. of crude adamantanamine salt; m.p. 202-204° (dec.), (al26 -13° (c, 1% in methanol). Following trituration with 50 ml. of boiling acetonitrile and cooling, the pale tan solid salt weighed 9.4 g.; m.p. 202-204° (dec.), [a]25 -13° (c, 1% in methanol).
The above adamatanamine salt -is suspended in 40 ml. of ethyl acetate, stirred, and treated with IN hydrochloric acid. When two clear layers are obtained they are separated, the aqueous phase is extracted with additional ethyl acetate (3 x 40 ml.), the combined organic layers are dried (MgSO^), and the solvent evaporated, finally at 0.2 mm. and 40°, to yield 5.8 g. (72%) of N-carbobenzyloxy-4,4-(1-methylethyl48331 - 67 enedioxy)-L-proline as a yellow-orange viscous syrup. c) 4,4-(1-Methylethylenedloxy)-L-proline A solution of the above N-carbobenzyloxy-4,4(l-methylethylenedioxy)-L-proline (5.6 g., 0.017 mole) in 150 ml. of 2:1 methanol-water is treated with 1.6 g. of 5% palladium-carbon catalyst and shaken under 3 atmospheres of hydrogen for five hours.
The catalyst is filtered off under nitrogen, washed with methanol, and the combined filtrates evaporated, finally at 0.1 - 0.2 mm. to give a crystalline residue. The latter is suspended in 200 ml. of methanol and the evaporation repeated. The solid residue is rubbed under ether (evaporation again repeated) to yield 3.0 g. (94%) of pale tan 4,4-(1-methylethylenedioxy)L-proline; m.p. 219-221° (dec.); preceded by gradual C λ darkening and sintering; [α]θ -22° (c, 1% in 1:1 ethanol-water). d) [7(S),8S]-7-[3-(Acetylthio)-2-methyl-l-oxopropylll,4-dioxd-7-a2aspiro[4.43nonane-2-methyl-8-carboxyIic acid The 4,4-(1-methylethylenedioxy)-L-proline (2.8 g., 0.015 mole) is reacted with 3.0 g. (0.017 mole) of D-3-acetylthio-2-methylpropionyl chloride in 40 ml. of water according to the procedure of Exanple 1 (e) to give 5.0 g. of a viscous yellow product. The latter is treated with 2.8 g. of dicyclohexylamine in 45 ml. of ethyl acetate to yield 4.2 g. of nearly colorless (7(S),8S]-7-(3-(acetylthio)2-methyl-l-oxopropyl)-1,4-dioxo-7-azaspiro[4.4]nonane2-methyl-8-carboxylic acid, dicyclohexylamine salt; 43321 m.p. 170-172° (s, 168°); [a]25 -58°; (c, 1% in ethanol). Following crystallization from 12 ml. of acetonitrile, the colorless solid salt weighs 3.85 g. (515); m.p. 170 - 172° (s. 168°); . ,25 [D Anal. -57°, Calc1 , (c, 15 in ethanol). 'd. for:C14H21N°6S ’ C12H23N: c, 60.90; H, 8.65; N, 5.46; S, 6.26 Found: : C, 60.93; H, 8.72; N, 5.43; S, 6.35.
The dicyclohexylamine salt is converted to the 10 free acid by suspending 3.8 g. in ethyl acetate and treating with 45 ml.· of 105 potassium bisuifate and stirring until two layers are obtained. After separating, the aqueous phase is extracted with ethyl acetate (4 x 40 ml.), the organic layers are combined, dried (MgSO^) and the solvent evaporated to give 2.5 g (515) of colorless solid [7(S),8S]-7-(3-(acetylthio)-2 methyl-l-oxopropyl]-1,4-dioxo-7-azaspiro[4.4]nonane2-methyl-8-carboxylic acid, m.p. 65 - 68° (s. 48°); (a)2® -100°, (c, 15 in ethanol). e) [7 (S),8SJ-7-(3-mercapto-2-methyl-l-OXopropyl)-1,4dioxo-7-azaspiro(4.4]nonane-2-methyl-8-carboxylic acid The product from part (d) is hydrolyzed with concentrated ammonia according to the procedure of Exanple 2 to give 2.05 g. of [7(S),8S]-7-(3-mercapto-2-nethyl-l25 oxopropyl)-l,4-dioxo-7-azaspiro r4.4]nonane-2-methyl-8-carboxylic acid as a viscous colorless oil, (o]2®-57° (c, 1% in ethanol).
Examples 42 - 75 Following the procedure of Example 41 the dimethoxy substituted compound of Column 1 (or its alkyl ester, is treated with the diol or dithiol 48321 of Column II to yield the spiro intermediate of column III. Removal of the N-protecting group (and the alkyl ester group) and acylation with the acyl chloride of Column IV yields the product of Column V which can then be hydrolyzed to the product of Column VI.
Col. I Col. II H C Jo CH, \ / c (H2C)p H1, Cbz-N C-rCOOH I H /X X1 X2 I1 I2 Η H Col. Ill Col. IV R9 , R10 Z ‘«ix X z c p(k>, ι I Cbz-N--C-COOH ι H R -C-S- (CH) -C— C-Cl o ro - 70 Col. V ,(O '10 / ] X1X ZX2 r8-c-s-(ch)0 II c (H2?)P (CH ) I q C-COOH I H Col. VI *9 Λθ \ Z z(c^ xv x, 1\ / 2 /C\ I4 HS-(CH); R, 0 t 3 ll 25’p "Λ - C-COOH I H 4*8321 ο m cd tf MS \ □ r\ \ / u -OS u — uj x Oi s Example Ol «tf I u ΙΛ £ CM U \ CM o s CM £ £ 0-0 Β Q —- W B £-O > U n £ O -O £ CM £ Ο — O £ CM £ O — « £ CM £ <9 <3· P*· as ? H. CO 4-9821 ffi U —OX □ —« X CM CM CH-CH. r*j 1Λ ΙΛ in ιβ in U") - 75 ,0 Γ* tn GO «η Cl Cl Β t δ-S Ιό) *CM δ X ϋ — to CM O-S Μ δ-δ / ί δ-δ \ δ-δ CM «Μ y_g Β o - δ (Μ Β δ δ-δ \ ζ Ζ°\ g ϋ υ — ο η cm Β « <Μ σι r* & - 78 η -Τ’ ϋ u r-< (Ν <Μ Η Ο Γ* Ρ* (Μ Λ Γ* Ρ* Ρ* Example» 75 - 124 Following the procedure of Exanple 41 the disubstituted compound of Column X (or its alkyl ester) is treated with a molar equivalent of the alcohol or thiol of Column II to yield the compound shown in Column III. Alternatively, by treating the dimethoxy substituted compound of formula I (or its alkyl ester) with a molar excess of the alcohol or thiol of Column II one obtains the disubstituted compound of Column IV. Removal of the N-protecting group (and the alkyl.ester group) from the intermediate of either Column III or IV followed by acylation with the acid chloride of Column V yields the product of Columns VI and VII, respectively.
These compounds can then be hydrolyzed to the products of Columns VIII and IX, respectively, Col. I Col. II H Cbz-N C-COOH 4S32A - 80 Col. HI Col. IV 1H2CIP (CHgiq (H2op X, x2 / \ Cbz-N — C-COOH ι H Cbz-N(CH_) I 2 « - C-COOH ι H Col. V 0 R4 R3 ? n Γ ι 1' Vc-S-ccH)m-c-c-ci Col. VI R |2 X1 0 Ra R3 ? I| I4 ι3 ll R^-C-S-(CH)m~C — C (H C) 2. p «"2>, . U--C-COOH I H - 81 Col. VII *2 X2 X / R 0 I3 II / (V’p (?H2>q R -C-S-(CH) -C— C8 m | RC-COOH ι H Col. VIII X1 (H C) 2, p HS-(CH) -Cm I •N (CH,) I 2 q - C-COOH I H 43321 - 82 Col. IX X7 Λ HS-(CH)--C— C m (CSV I 2g - C-COOH I H «I Exaqple 48321 .ζ. (Ο1 I d X υ ό ? ( δ ά -O-CH„C=CII σι δ ά ιη χ d Ο σι σι δ ? •Η σι σι Φ χρ φ co Φ «4 η ο ο r* ο 48321 Ί. 9ΤΤ 4S324 123 1 2 -O-CH -O-CH -CH=CH - 89 Example 125 (S,S, S,S)-7,71 - [Pithiobl's (2-methyl-l-oxo-3,l-propanediyl)lbis[lj4-dioxa-7-azaspiro [4.4]nonane-8-carboxylic acid] [7(S),8S]-7-(3-Mercapto-2-methyl-l-oxopropyl)1,4-dioxo-7-azaspiro[4.4]nonane-8-carboxylic acid (3.0 g., 0.0109 mole) from Example 2 is dissolved in 80 ml. of water and the pH is adjusted to 6.5 with IN sodium hydroxide. To this stirred solution is added dropwise a total of 11 ml. of 0.5 M iodine solution in 95% ethanol (6.34 g. iodine/50 ml. solution) while maintaining the pH at 5.5 to 6.5 with IN sodium hydroxide. After 15 minutes, a trace of excess iodine is removed with dilute sodium thiosulfate and the solution is concentrated to approximately 50 ml., cooled and acidified with 1:1 hydrochloric acid. Methylene chloride (30 ml.) is added and the mixture is saturated with sodium chloride, stirred, and the layers separated. The aqueous phase is extracted with additional methylene chloride (3 x 20 ml.), the combined organic layers dried (MgSO^), and the solvent evaporated, finally at 0.2 mm. The brittle residue is rubbed under ether an1 combined layers dried (MgSO^). Evaporation and trituration with ether as above yields 2.2 g. (73%) of cream-colored amorphous solid (S,S,S,S)-7,7'90 [dithiobis (2-raethyl-l-oxo-3,1-propanediyl)Ibis [1,4γ dioxo-7-azaspiro[4.4]nonane-8-oarboxylic acid]; m.p. 61-63° (foaming), (s. 50°), [a]26 -92°, (c, IS in ethanol).
Anal. Calc'd. for c22H32H2°10S ' H2°’ C, 46.63; H. 6.05; N, 4.94; S, 11.31 Found: C, 46.52; H, 6.29; N, 4.63; S, 10.96.
Example 126 (5.5.5.5) -7,7'-[Dithiobis(2-methyl-oxo-3,1-propanediyl)]bis[7-a2a-l,4-dithiaspiro[4.4]nonane-8carboxylic acid] [7(S),8S]-7-(3-Mercapto-2-methyl-l-oxopropyl)~ 7-aza-l,4-dithiaspiro[4.4]nonane-8-carboxylic acid frora Example 10 is reacted with iodine according to the procedure of Example 125 to yield (S,S,S,S)-7,7'[dithiobis(2-methyl-l-oxo-3,1-propanediyl)]bis[7-aza-l,4-dithiaspiro[4.4]nonane-8-carboxylic acid].
Example 127 (5.5.5.5) —1,11 -[Dithiobis(2-methyl-l-oxo-3,1-propanediyl) ]bis[4,4-dimethoxy-L-proline] (S)-1-(3-Mercapto-2-methyl-l-oxopropyl)-4,4dimethoxy-L-proline from Example 4 is reacted with iodine according to the procedure of Example 125 fco yield (S,S,S,S)-1,1’-[dithiobis(2-methyl-l-oxo3,1-propanediyl)]bis[4,4-dimethoxy-L-proline].
Example 128 [7(S),8(S)]-7-[3-(Acetylthio)-2-methyl-l-oxopropyl]l,4-dioxo-7-azaspiro[4.4]nonane-8-carboxylic acid, methyl ester A solution of the product of Example 1 in - 91 ether is treated with a slight excess of diazomethane. After standing at room temperature for two hours, the solvent is evaporated to give [7 (S),8S]-7- [3-(acetylthio,-2-methyl-l-oxopropyl]1,4-dioxo-7-azaspiro[4.4]nonane-8-carboxylic acid, methyl ester.
Example 129 [7(S),8S]-7-(3-Mercapto-2-methyl-I-oxopropyl)-l,4dioxo-7-azaspiro[4.4]nonane-8-carboxylic acid, methyl eater The product.from Example 128 is hydrolyzed with concentrated ammonia according to the procedure of Example 2 to yield [7(S),8SJ-7-(3-mercapto-2methyl-l-oxopropyl)-1,4-dioxo-7-azaspiro[4.4]nonane8-carboxylic acid, methyl ester.
Example 130 (S)—1—[3—(Acetylthio)-2-methy1-1-oxopropyl]-4,4dimethoxy-L-proline, methyl ester A solution of the product from Example 3 in ether is treated with a slight excess of diazomethane. After standing at room temperature, the solvent is evaporated to give (S,-l-[3-(acetylthio)2-methyl-l-oxopropyl]-4,4-dimethoxy-L-proline, methyl ester.
Example 131 (S)-1-(3-Mercapto-2-methyl-l-oxopropyl)-4,4-dimethoxyL-proline, methyl ester The product from Example 130 is hydrolyzed with concentrated ammonia according to the procedure of Example 4 to yield (S)-l-(3-mercapto-2-methyl-l49321 - 92 oxopropyl)-4,4-dimethoxy-L-prolina, methyl ester. Example 132 [7(5),8Sl-7-(3-Mercapto-2-mgthyl-l-oxopropyl)-l,4dioxo-7-azaspiro[4.4]nonane-8-carboxylic acid, sodium salt A solution of 1.0 g. of the product of Example 2 is dissolved in 10 ml. of water and treated with one equivalent of sodium bicarbonate. The solution is freeze-dried to give[7(S),8S]-7-(310 mercapto-2-methy1-1-oxopropyl)-l,4-dioxo-7azaspiro[4.4]nonane-8-carboxylic acid, sodium salt.
In a similar manner, by employing potassium bicarbonate the corresponding potassium salt is obtained.
Example 133 (S)-1-(3-Mercapto-2-methy1-1-oxopropyl)-4,4-dimethoxy L-proline, sodium salt A solution of 1.0 g. of the product of Example 4 is dissolved in 10 ml.of water and treated with one equivalent of sodium bicarbonate. The solution is freeze-dried to give (S)-l-(3-mercapto2-methyl-l-oxopropyl)-4,4-dimethoxy-L-proline, sodium salt.
In a similar manner, by employing potassium bicarbonate the corresponding potassium salt is obtained.
Example 134 1000 tablets each containing the following ingredients : [7(S),8S]-7-(3-Mercapto30 Ί - 93 2-methyl-l-oxopropyl)-1, 4-dioxo-7-azaspiro[4.4Jnonane8-carboxylic acid 100 mg.
Corn starch 50 mg.
Gelatin 7.5 mg.
Avicel (microcrystalline cellulose) 25 mg.
Magnesium stearate 2.5 mq. 185 mg. are prepared (from sufficient bulk quantities) by mixing the [7 (S) ,8S].-7-(3-mercapto-2-methyl-loxopropyl)-1,4-dioxo-7-azaspiro[4.4]nonane-8carboxylic acid and corn starch with an aqueous solution of the gelatin. The mixture is dried and ground to a fine powder. The Avicel and then the magnesium stearate are admixed with granulation.
This mixture is then compressed in a tablet press to form 1000 tablets each containing 100 mg. of active ingredient.
Example 135 Tablets each containing 100 mg. of (S)-1-(3-mercapto-2-methyl-l-oxopropyl)-4,4-dimethoxyL-proline are produced as described in Example 134.
Example 136 1000 tablets each containing 50 mg. of [7(S), 8SJ-7-(3-mercapto-2-methyl-l-oxopropyl)-l,4-dioxo7-azaspiro[4.4]nonane-8-carboxylic acid are produced from the following ingredients - 94 (7(S),8S]-7-(3-mercapto-2methyl-l-oxopropyl)-l,4dioxo-7-azaspiro[4.4]nonane-8- carboxylic acid 50 g· Lactose 100 g· Avicel 150 g· Corn starch 50 g- Magnesium stearate 5 g.
The [7(S),8S]-7-[3-mercapto-2-methyl-l10 oxopropyl)-1,4-dioxo-7-azaspiro[4.4]nonane-8carboxylic acid, lactose, and Avicel are admixed, then blended with the corn starch. Magnesium stearate is added. The dry mixture is compressed in a tablet press to form 1000 355 mg. tablets each containing 50 mg. of active ingredient. The tablets are coated with a solution of Methocel E 15 (methyl cellulose) including as a color a lake containing yellow #6.
Example 137 Tablets each containing 50 mg. of (S)-l(3-mercapto-2-methyl-l-oxopropyl)-4,4-dimethoxy-Lproline are produced as described in Example 136.
Example 138 Two piece ¢1 gelatin capsules each containing 100 mg. of [7(S),8S]-7-(3-mercapto-2-methyl-loxopropyl) -1,4-dioxo-7-azaspiro[4.4]nonane-8carboxylic acid, sodiun salt, are filled with a mixture of the following ingredients: - 95 £7(S),8S]-7-(3-mercapto-2roethy1-1-oxopropyl)-1,4-dioxo7-a2aspj.ro [4.4] nonane-8- carboxylic acid, sodium salt 100 mg. Magnesium stearate 7 mg. Lactose 193 mg. Example 139 Gelatin capsules containing 100 mg. of 500 . 25 5 g· gg· g· (S)-1-(3-mercapto-2-methyl-l-oxopropyl)-4,4-dimethoxyL-proline, sodium salt are produced as described in Example 138.
Example 140 An injectable solution is produced as follows: [7(S),8S]-7-(3-Mercapto2-methyl-l-oxopropyl)-1,4dioxo-7-azaspiro[4.4]nonane8-carboxylic acid Methyl paraben Propyl paraben Sodium chloride Water for injection qs.
The active substance, preservatives and sodium chloride are dissolved in 3 liters of water and then the walume is brought up to 5 liters. The solution is filtered through a sterile filter and aseptically filled into presterilized vials which are then closed with presterilized rubber closures. Each vial contains 5 ml. of solution in a concentration of 100 mg· - 49321 - 96 10 active ingredient per ml. of solution for injection. Example 141 An injectable solution containing (S)-l(3-mercapto-2-methy1-1-oxopropyl)-4,4-dimethoxy-Lproline is prepared as described in Example 140.
Example 142 6000 tablets each containing the following ingredients : (7(S),8S]-7-(3-mercapto-2-methyl1-oxopropyl)-1,4-dioxo-7-azaspiro[4.4]nonane-8-carboxylic acid 100 Avicel (microcrystalline 100 cellulose) Hydrochlorothiazide 12.5 Lactose U.S.P. 113 Corn starch U.S.P. 17.5 Stearic acid U.S.P. 7 mg. mg. mg. mg. mg. mg. 350 mg. are produced from sufficient bulk quantities by slugging the (7(S),8S]-7-(3-mercapto-2-methyl-loxopropyl)-1,4-dioxo-7-azaspiro(4.41 nonane-8carboxylic acid, Avicel and a portion of the stearic acid. The slugs are ground and passed through a #2 screen, then mixed with the hydrochlorothiazide, lactose, corn starch and remainder of the stearic acid. The mixture is compressed into 350 mg. capsule shaped tablets in a tablet press. The tablets are scored for dividing in half. - 97 Example 143 Tablets each containing (S,-l-(3-mercapto-2methy1-1-oxopropyl)-4,4-dimethoxy-L-proline and hydrochlorothiazide can be prepared as described in Example 142.
The product of-Examples 1, 3 and 6 to 133 can also be formulated according to the procedures of Examples 134-143. 48321
Claims (15)
1. (1) coupling a substituted proline or pipecolic acid of the formula R-ι R, I 1 I 2 Χ Γ\^^-' Χ 2 I Γ HN-ς—COOR I* H with an acid of the formula ?4 RI—S—(CH) —C—COOH 5 m j R 6 wherein Rj is hydrogen or a hydrolyzably or chemically removable protecting group, according to conventional methods, or (2) treating a compound of the formula i? C. (H.C) f 3 » Wq (CH) -C-Οιτι •C-COOH * H wherein Rj is hereinabove defined with alcohols or thiols selected from the group consisting of R^X^H, R 2 X 2 H an< 5 \c) t / R 10 48321 - 133 to form a product wherein R- is hydrogen or a hydrolyzably or chemically removable protecting group, and removing said protecting group to form a product wherein Rg is hydrogen, and oxidizing said products
2. , or H 2? / CH 2\ 1θ· The compound of Claim 17 wherein R, R^, 2-\O> ' CH k -CH or -C^Q 'N m is zero or one; and R? is hydrogen, methyl, methoxy, methylthio, chloro, bromo, fluoro, trifluoromethyl or hydroxy. 2 Π Rg is hydrogen or lower alkyl provided that R, is lower alkyl only when R, is lower alkyl; o 3 m is zero, one or two; n is one, two, or three; t is two or three; R? is hydrogen, lower alkyl of 1 to 4 carbons, lower alkoxy of 1 to 4 carbons, lower alkylthio of 1 to 4 carbons, chloro, bromo, fluoro, trifluoromethyl, or hydroxy; Rg and R^ q are both hydrogen, both lower alkyl, or one is hydrogen and the other is lower alkyl, halo substituted lower alkyl, hydroxy substituted lower alkyl, /< 2) | IN R 5 is hydrogen, a hydrolyzably removable protecting, a chemically removable protecting group, or provided that neither R^ or R^ is -(CH 2 ) n -SH R 1 R 2 ι *· r x i /2 ^c Z /- \ R R 0 (H,C) CCH,) | 4 | 3 II 2 | p I 2q -S-(CH) -C —C -N - C-COOR m , , R, H with the proviso that, when p and g are 1, the proline is in the L-form.
3. The compound of Claim 1 wherein p is one and q is two. 4. ^)321 - 112 characterized by: 4-9321 - 109 27. A process for preparing a compound of the formula R -S-(CH)— 5 I» R (H,C) 2, p '“Λ N -- C-COOR H or a pharmaceutically acceptable salt thereof wherein 42321 - 110 R is hydrogen or lower alkyl; Rg and Rg are independently selected from the group consisting of lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, halo substituted lower alkyl, hydroxy substituted lower alkyl, - ^ CH 2^nlO ' or R i anc3 R 2 3 ° 3n together in a polymethylene chain of the formula \ / (C) / 4-9321 - 104 1C -CH 2701 X N m is zero or one; and Rg is hydrogen, methyl, methoxy, methylthio, chloro, bromo, fluoro, trifluoromethyl, or hydroxy. 4-9321 - 103 or -(ch 2 ) 4o Rg is hydrogen, a hydrolyzably removable protecting group, a chemically removable protecting group, or provided that neither Rg nor R^ is -(CH,) -SH 2 n
4. The compound of Claim 1 wherein p and q are both one 101 4-9321 - 99 polyroethylene chain of the formula /\ X^, x 2 and Xj are independently selected from oxygen and sulfur; 5. Wherein Rg is hydrogen to form the product wherein Rg -S—(CH) —C—CO—N-Cr COOH » I 28. A composition for treating hypertension comprising a diuretic and a compound according to 5 R g and R^ Q are both hydrogen, both lower alkyl, or one is hydrogen and the other is lower alkyl, halo substituted lower alkyl, hydroxy substituted lower alkyl, - (CU,) - (CIL·) ’ll · or '· and IK Rg is hydrogen, a hydrolyzably removable protecting, a chemically removable protecting group, or provided that neither Rg or is -(CH 2 ) n -SH X 1 /2 R, 0 (H,C) i 3 ii 2 1 P X’q -S-(CH) -C — C m , R_ C-COOR I H with the proviso that, when p and g are 1, the proline is in the L-form 5 capto-2-trifluoromethyl-l-oxopropyl)-1,4-dioxo-7azas-piro [4.4]nonane-8-carboxylic acid. 25. The compound of Claim 8 wherein Rg and R. are other than -(CH.) -SH and R_ is 4 2 η o -S-(CH) -C— C m 26. The compound of Claim 25, (S,S,S,S)7,7'-[dithiobis(2-methyl-1-oxo-3,1-propanediyl)]bis[l,4-dioxo-7-azaspiro[4.4]nonane-8-carboxylic acid ]. 5 22. The compound of Claim 18, [7(S),8S]-7(3-mercapto-2-methyl-l-oxopropyl)-1,4-dioxo-7azaspiro[4.4]nonane-2-methyl-8-carboxylic acid. - ιοε 23. The compound of Claim 17 wherein R, R^, Rg and R g are hydrogen, Rg is trifluoromethyl; and m is one. 24. The compound of Claim 23, (8S)-7-(3-mer 5 Rg and R g are hydrogen, Rg is methyl; and m is one. 19· The compound of Claim 18, [7(S),8S]7-(3-mercapto-2-methyl-l-oxopropyl)-1,4-dioxo-7azaspiro[4.4]nonane-8-carboxylic acid. 20 · The compound of Claim 18,(2(S),3S]-2-(3θ mercapto-2-methyl-l-oxopropyl)-6,10-dioxo-2-azaspiro[4.5]decane-3-carboxylic acid. 21. The compound of Claim 18, [7(S),8S]-7(3-mercapto-2-methy1-1-oxopropyl)-7-aza-l,4-dithiaspiro [4.4]nonane-8-carboxylic acid.
5. 'ine compouna ox Claim 4 wherein X^ and X 2 are independently selected from oxygen or sulfur; R is hydrogen or lower alkyl; R^ and R 2 each is lower alkyl of 1 to 4 carbons or form two joined methylene groups; R g and R 4 each is hydrogen or lower alkyl of 1 to 4 carbons; Rg is hydrogen, lower alkanoyl of 1 to 4 carbons, or benzoyl; R g is hydrogen, and m is zero or one. 5 Rj and R^ are independently selected from hydrogen, lower alkyl, lower alkylthio, -{CH 2 ) n - SH, and halo substituted lower alkyl; Rg is hydrogen or lower alkyl provided that
6. The compound of Claim 4 wherein X^ and X 2 each is oxygen; R, R 4 , Rg and R g each is hydrogen; R^ and R 2 each is lower alkyl of 1 to 4 carbons or R^ and R 2 each is methylene and join to complete the ethylenedioxy ring; Rg is methyl; and m is one.
7. The compound of Claim 4 wherein X 2_~ R ^ and X 2 -R 2 C0ln P^ ete an ethylenedioxy ring.
8. A compound of the formula or such a compound in a pharmaceutically acceptable salt form wherein R is hydrogen or lower alkyl; R^ and R 2 are independently selected from lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, halosubstituted lower alkyl, hydroxy substituted lower alkyl, 1C - 102 -(CHg) jTjp , and - (CHg) V-O | , or and Rg join together in a polymethylene chain of the formula R 9\ / R : (C) t / x X^, Xg and Xg are independently selected from of oxygen ana sulfur; Rg and R 4 are independently selected from hydrogen, lower alkyl, lower alkylthio, -(CH,) -SH, and halo substituted lower alkyl;
9. The compound of Claim 8 wherein R is hydrogen; R^ is hydrogen; Rg and R g are both lower alkyl of 1 to 4 carbons or R g is hydrogen and Rj is hydrogen, lower alkyl of 1 to 4 carbons, trifluoromethyl, methylthio, or mercaptomethyl: Rg is hydrogen, lower alkanoyl of 1 to 4 carbons, or benzoyl; X^ and X 2 are oxygen or sulfur; and Rj are lower alkyl of 1 to 4 carbons, or 10. Claim 1. 29. T. process according to claim 27, substantially as herein described with reference to the Examples. 30. A compound as defined in Claim 1 whenever prepared by a process according to Claim 27 or 29. 10 Xg, Xg and Xg are independently selected from the group consisting of oxygen and sulfur; Rg and R^ are independently selected from the group consisting of hydrogen, lower alkyl, lower alkylthio, -(CH ) -SH, and halo substituted lower 2 n 15 alkyl; Rg is hydrogen or lower alkyl provided that R r is lower alkyl only when R, is lower alkyl; 0 j m is zero, one or two; n is one, two or three; p and q are each one or two provided that both are not two; t is two or three; - Ill R 7 is hydrogen, lower alkyl of 1 to 4 carbons, lower alkoxy of 1 to 4 carbons, lower alkylthio of 1 to 4 carbons, chloro, bromo, fluoro, trifluoromethyl, or hydroxy;
10. The compound of Claim 9 wherein R is hydrogen; is hydrogen; Rg and R g are both methyl or R. is hydrogen and R, is hydrogen, methyl, triD J fluoromethyl, methylthio, or mercaptomethyl; hydrogen, acetyl, or benzoyl; same; R^ and Rg are methyl, ethyl, Rg is X^ and X 2 are the -CH 10 2. The compound of Claim 1 wherein p is two and q is one. 10 Rg is lower alkyl only when Rj is lower alkyl; m is zero, one or two; n is one, two or three; p and q are each one or two provided that both are not two; 15 t is two or three; R? is hydrogen, lower alkyl of 1 to 4 carbons, lower alkoxy of 1 to 4 carbons, lower alkylthio of 1 to 4 carbons, chloro, bromo, fluoro, trifluoromethyl, or hydroxy; 20 R g and R 1Q are both hydrogen, both lower alkyl, or one is hydrogen and the other is lower alkyl, halo substituted lower alkyl, hydroxy substituted lower alkyl, - IOC (CH ) χο) · -< c » 2 >»-n or ; and -(CH,)
11. The compound of Claim 10 wherein R, S 4 , Rg, and Rg are hydrogen; R g is methyl; m is one; and R^ and Rg are both methyl or ethyl.
12. The compound of Claim 11 wherein Χ χ and Xg are both oxygen.
13. The compound of Claim 12, (S)-l(3-mercapto-2-methyl-l-oxopropyl)-4,4—dimethoxy—L— proline. - 105
14. The compound of Claim 12, (S)-l-{3-mercapto- 2-me thy 1-1-oxopropyl) -4 ,4-diethoxy-Lproline. 15. The compound of Claim 8 wherein R is hydrogen; R^ is hydrogen; R^ and R g are both lower alkyl of 1 to 4 carbons or R g is hydrogen and Rg is hydrogen, lower alkyl of 1 to 4 carbons, trifluoromethyl, methylthio, or mercaptomethyl; R g is hydrogen, lower alkanoyl of 1 to 4 carbons, or benzoyl; X^ R^ and Xj-Rj join to form \ Z R 9 X- Z K 9 - C .. \ R 10 1 1 R 10 , . R 10 1 1 R io ° z° s s ‘10 Ίο x R 10 c H,C CH, * I t 4 H 2 C CH, or H 2 C V* 10 / \ CH, - 106 Rg and Rj.q are both hydrogen or both lower alkyl of 1 to 4 carbons; or Rg is hydrogen and R^g is lower alkyl of 1 to 4 carbons, hydroxy substituted lower alkyl of 1 to 4 carbons, or halogen substituted lower alkyl of 1 to 4 carbons; m is zero or one. 16. The compound of Claim 15 wherein R g and R are both hydrogen or R o is hydrogen 10 y and R^g is methyl, hydroxymethyl, or trifluoromethyl. 17. The compound of Claim 16 wherein R is hydrogen; R 4 is.hydrogen; Rg and R g are both methyl or R g is hydrogen and Rg is hydrogen, methyl, trifluoromethyl, methylthio or mercaptomethyl; Rg is hydrogen, acetyl, or benzoyl; and k^-Rj and Xg-Rg join to form - 107 H,C — CH 2 I I 2 0 0 H-C — CH-CH, 2| , J V- CH 2 H 2 C — CH-CH 3 H 2 C CH, Z 2\ CH
15. 31. A compound according to claim 1 or claim 8 substantially as herein described.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97231478A | 1978-12-22 | 1978-12-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
IE792468L IE792468L (en) | 1980-06-22 |
IE49321B1 true IE49321B1 (en) | 1985-09-18 |
Family
ID=25519507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE2468/79A IE49321B1 (en) | 1978-12-22 | 1979-12-19 | Derivatives of mercaptoacyl prolines and pipecolic acids |
Country Status (31)
Country | Link |
---|---|
JP (1) | JPS5594357A (en) |
AT (1) | AT374174B (en) |
AU (1) | AU533149B2 (en) |
BE (1) | BE880815A (en) |
CA (1) | CA1132985A (en) |
CH (1) | CH642065A5 (en) |
CS (1) | CS215036B2 (en) |
DD (1) | DD148338A5 (en) |
DE (1) | DE2951200A1 (en) |
DK (1) | DK159115C (en) |
ES (2) | ES487180A0 (en) |
FI (1) | FI70886C (en) |
FR (1) | FR2444669A1 (en) |
GB (1) | GB2039478B (en) |
GR (1) | GR78384B (en) |
HK (1) | HK15684A (en) |
HU (1) | HU179644B (en) |
IE (1) | IE49321B1 (en) |
IL (1) | IL58930A (en) |
IT (1) | IT1126841B (en) |
LU (1) | LU82023A1 (en) |
NL (1) | NL7909246A (en) |
NO (1) | NO153569C (en) |
NZ (1) | NZ192449A (en) |
PH (1) | PH19213A (en) |
PL (1) | PL133414B1 (en) |
PT (1) | PT70620A (en) |
SE (1) | SE451839B (en) |
SU (1) | SU1115668A3 (en) |
YU (1) | YU314879A (en) |
ZA (1) | ZA796720B (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2455585A1 (en) * | 1979-05-04 | 1980-11-28 | Ono Pharmaceutical Co | OXOAMINOACID DERIVATIVES, MANUFACTURING METHOD AND PHARMACEUTICAL COMPOSITION |
US4288368A (en) * | 1979-07-30 | 1981-09-08 | E. R. Squibb & Sons, Inc. | Dithioacylproline derivatives |
US4291040A (en) * | 1979-10-22 | 1981-09-22 | E. R. Squibb & Sons, Inc. | Mercaptoacyl derivatives of 4-disubstituted prolines and 4-substituted dehydroprolines |
US4356182A (en) * | 1979-10-22 | 1982-10-26 | E. R. Squibb & Sons, Inc. | Mercaptoacyl derivatives of 4-disubstituted prolines |
HU184082B (en) * | 1979-12-29 | 1984-06-28 | Egyt Gyogyszervegyeszeti Gyar | Process for preparing 1-3-/3mercapto-/2s/-methyl-propinyl/-pyrrolidine-/2s/-carboxylic acid |
US4284624A (en) | 1980-05-02 | 1981-08-18 | E. R. Squibb & Sons, Inc. | Mixed disulfides |
US4316905A (en) * | 1980-07-01 | 1982-02-23 | E. R. Squibb & Sons, Inc. | Mercaptoacyl derivatives of various 4-substituted prolines |
US4311705A (en) * | 1980-10-06 | 1982-01-19 | E. R. Squibb & Sons, Inc. | Carboxyalkanoyl and hydroxycarbamoylalkanoyl derivatives of substituted prolines |
US4462943A (en) * | 1980-11-24 | 1984-07-31 | E. R. Squibb & Sons, Inc. | Carboxyalkyl amino acid derivatives of various substituted prolines |
US4416831A (en) | 1981-04-27 | 1983-11-22 | E. R. Squibb & Sons, Inc. | Amino and substituted amino phosphinylalkanoyl compounds |
US4374131A (en) | 1981-04-27 | 1983-02-15 | E. R. Squibb & Sons, Inc. | Amino and substituted amino phosphinyl-alkanoyl compounds |
US4416833A (en) | 1981-05-04 | 1983-11-22 | E. R. Squibb & Sons, Inc. | Substituted carbonyl phosphinyl-alkanoyl compounds |
US4381297A (en) | 1981-05-04 | 1983-04-26 | E. R. Squibb & Sons, Inc. | Substituted carbonyl phosphinyl-alkanoyl compounds |
US4555506A (en) * | 1981-12-24 | 1985-11-26 | E. R. Squibb & Sons, Inc. | Phosphorus containing compounds and use as hypotensives |
US4560680A (en) * | 1982-03-15 | 1985-12-24 | E. R. Squibb & Sons, Inc. | Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors |
US4452791A (en) * | 1982-03-15 | 1984-06-05 | E. R. Squibb & Sons, Inc. | Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors |
CA1258853A (en) * | 1982-04-30 | 1989-08-29 | Rudiger D. Haugwitz | Substituted 4-phenoxy prolines |
US4703043A (en) * | 1982-06-23 | 1987-10-27 | E. R. Squibb & Sons, Inc. | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensive |
US4452790A (en) * | 1982-06-23 | 1984-06-05 | E. R. Squibb & Sons, Inc. | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives |
US4616005A (en) * | 1982-06-23 | 1986-10-07 | E. R. Squibb & Sons, Inc. | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives |
US4567166A (en) * | 1982-07-14 | 1986-01-28 | E. R. Squibb & Sons, Inc. | Amino and substituted amino phosphinylalkanoyl compounds useful for treating hypertension |
US4709046A (en) * | 1983-05-09 | 1987-11-24 | E. R. Squibb & Sons, Inc. | Acylmercaptoalkanoyl and mercaptoalkanoyl spiro compounds |
AU632596B2 (en) * | 1989-08-21 | 1993-01-07 | E.R. Squibb & Sons, Inc. | Phosphonate substituted amino or imino acids useful as antihypertensives |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4046889A (en) * | 1976-02-13 | 1977-09-06 | E. R. Squibb & Sons, Inc. | Azetidine-2-carboxylic acid derivatives |
US4091024A (en) * | 1976-12-03 | 1978-05-23 | E. R. Squibb & Sons, Inc. | Pyrrolidine and piperidine-2-carboxylic acid derivatives |
IT7851510A0 (en) * | 1977-10-28 | 1978-10-16 | Sandoz Ag | AMIDES OF CYCLIC AMINO ACIDS THEIR PREPARATION AND THEIR APPLICATION AS MEDICINES |
PH15381A (en) * | 1978-02-21 | 1982-12-17 | Squibb & Sons Inc | Halogen substituted mercaptoacylamino acids |
CA1144930A (en) * | 1978-08-11 | 1983-04-19 | Miguel A. Ondetti | Mercaptoacyl derivatives of substituted prolines |
-
1979
- 1979-12-07 CA CA341,486A patent/CA1132985A/en not_active Expired
- 1979-12-11 ZA ZA00796720A patent/ZA796720B/en unknown
- 1979-12-11 AU AU53714/79A patent/AU533149B2/en not_active Ceased
- 1979-12-12 IL IL58930A patent/IL58930A/en unknown
- 1979-12-13 GR GR60746A patent/GR78384B/el unknown
- 1979-12-13 GB GB7942991A patent/GB2039478B/en not_active Expired
- 1979-12-17 CS CS798891A patent/CS215036B2/en unknown
- 1979-12-18 NZ NZ192449A patent/NZ192449A/en unknown
- 1979-12-19 FR FR7931132A patent/FR2444669A1/en active Granted
- 1979-12-19 NO NO794181A patent/NO153569C/en unknown
- 1979-12-19 DE DE19792951200 patent/DE2951200A1/en not_active Ceased
- 1979-12-19 IE IE2468/79A patent/IE49321B1/en unknown
- 1979-12-19 PH PH23434A patent/PH19213A/en unknown
- 1979-12-20 AT AT0805479A patent/AT374174B/en active
- 1979-12-20 SE SE7910550A patent/SE451839B/en not_active IP Right Cessation
- 1979-12-20 CH CH1133979A patent/CH642065A5/en not_active IP Right Cessation
- 1979-12-21 LU LU82023A patent/LU82023A1/en unknown
- 1979-12-21 SU SU792860149A patent/SU1115668A3/en active
- 1979-12-21 IT IT51167/79A patent/IT1126841B/en active
- 1979-12-21 DD DD79218061A patent/DD148338A5/en not_active IP Right Cessation
- 1979-12-21 BE BE0/198709A patent/BE880815A/en not_active IP Right Cessation
- 1979-12-21 PT PT70620A patent/PT70620A/en unknown
- 1979-12-21 FI FI794027A patent/FI70886C/en not_active IP Right Cessation
- 1979-12-21 NL NL7909246A patent/NL7909246A/en not_active Application Discontinuation
- 1979-12-21 YU YU03148/79A patent/YU314879A/en unknown
- 1979-12-21 PL PL1979220609A patent/PL133414B1/en unknown
- 1979-12-21 ES ES487180A patent/ES487180A0/en active Granted
- 1979-12-21 HU HU79SU1047A patent/HU179644B/en not_active IP Right Cessation
- 1979-12-21 DK DK550079A patent/DK159115C/en not_active IP Right Cessation
- 1979-12-22 JP JP16747179A patent/JPS5594357A/en active Pending
-
1980
- 1980-02-20 ES ES488752A patent/ES488752A0/en active Granted
-
1984
- 1984-02-23 HK HK156/84A patent/HK15684A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IE49321B1 (en) | Derivatives of mercaptoacyl prolines and pipecolic acids | |
US4311697A (en) | Derivatives of mercaptoacyl prolines and pipecolic acids | |
US4046889A (en) | Azetidine-2-carboxylic acid derivatives | |
US4217359A (en) | Carbamate derivatives of mercaptoacyl hydroxy prolines | |
US4578474A (en) | Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids | |
US4390695A (en) | Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids | |
US4296113A (en) | Mercaptoacyl derivatives of keto substituted proline and pipecolic acid | |
CA1168245A (en) | Carboxyalkanoyl and hydroxycarbamoylalkanoyl derivatives of substituted prolines | |
US4757069A (en) | Pyridazodiazepine derivatives | |
EP0018104B1 (en) | Tetrahydroisoquinolines, their production and the compounds and pharmaceutical compositions containing them for use in the prevention or treatment of hypertension | |
US4296033A (en) | 4-Azido-1-mercaptoacyl proline | |
US4291040A (en) | Mercaptoacyl derivatives of 4-disubstituted prolines and 4-substituted dehydroprolines | |
US4241076A (en) | Halogenated substituted mercaptoacylamino acids | |
IE47971B1 (en) | Halogen substituted mercaptoacylamino acid | |
US4252943A (en) | Carbamate derivatives of mercaptoacyl hydroxy prolines | |
US4456761A (en) | 4-Substituted dehydroprolines | |
US4330548A (en) | Mercaptoacyl derivatives of keto substituted pipecolic acid | |
US4356182A (en) | Mercaptoacyl derivatives of 4-disubstituted prolines | |
US4709046A (en) | Acylmercaptoalkanoyl and mercaptoalkanoyl spiro compounds | |
US4499287A (en) | Certain-4-hydroxy-proline derivatives | |
CA1138452A (en) | Carbamate derivatives of mercaptoacyl hydroxy prolines | |
CA1138878A (en) | Mercaptoacyl derivatives of keto substituted proline and pipecolic acid | |
US4308388A (en) | 4-Azido-1-mercaptoacyl pipecolic acid | |
US4321392A (en) | Mercaptoacyl derivatives of 4-oxazolidine-carboxylic acids | |
GB2070586A (en) | Derivatives of Proline or Pipecolic Acid |